CUMULATIVE SUPPLEMENT 5

JAN'95-MAY'95

APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

15TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF MANAGEMENT
DIVISION OF DRUG INFORMATION RESOURCES

Prepared By
Division of Drug Information Resources
Office of Management
Center for Drug Evaluation and Research, FDA

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

15TH EDITION

Cumulative Supplement 5

MAY 1995

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

15TH EDITION

CUMULATIVE SUPPLEMENT 5
MAY 1995

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 15th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**ADD**> to the left of the line on which new information exists. The >**ADD**> symbol is then dropped in subsequent Cumulative Supplements for that item.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**DLT**> (DELETE) to the left of the line containing shaded print. The >**DLT**> symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the shaded print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 15th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 16th Edition.

1.2 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required

to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (film, extended release; transdermal*)	JUL 15, 1993 (58 FR 38129)
Nitroglycerin (tablet, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 05, 1985 (50 FR 27688)

*The Federal Register of July 15, 1993 (58 FR 38129) announced that the FDA was revoking the temporary exemption for nitroglycerin in a transdermal delivery system. Marketing of a drug product that is the subject of a conditionally approved ANDA may continue by meeting the requirements listed in the Federal Register. Firms wishing to submit a new ANDA before a drug product is approved (NDA or ANDA) and appears in the List should submit a 505(b)(2) application following the directions contained in the Federal Register. Nitro-Dur has been selected as the reference listed drug. The preamble to the final rule (57 FR 17958) states if there are multiple NDA's, the reference listed drug generally will be the market leader. This is the basis upon which Nitro-Dur was selected. In addition, the preamble states that, in multiple NDA situations, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. This is the case with Summit's Transderm-Nitro. The Office of Generic Drugs (OGD) has been requested to have a second listed drug as provided for in the Final Rule. OGD has granted this request. Therefore, at the time that Schering's and Summit's supplements are fully approved and their products are entered into the List, we will have two reference listed drugs for the nitroglycerin transdermal systems. Firms may, therefore, elect to conduct bioequivalence studies against either of these products. It is conceivable that a non-referenced listed drug may be fully approved and appear in the List; in this case, the Agency's referenced listed drug will not change and a 505(b)(2) application will be appropriate until the reference listed drugs are fully approved. Once they are fully approved, a 505(j) application will be the appropriate mechanism for an ANDA submission.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation

of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whiteworth Towne [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
BOOTS PHARMACEUTICALS INC (BOOTS)	KNOLL PHARMACEUTICAL COMPANY SUB BASF CORPORATION (KNOLL PHARM)
BRIAN PHARMACEUTICALS INC (BRIAN)	HYGENICS PHARMACEUTICALS INC (HYGENICS)
DORSEY LABORATORIES DIV SANDOZ WANDER INC (DORSEY)	SANDOZ CONSUMER HEALTH CARE GROUP DIV SANDOZ PHARMACEUTICALS CORP (SANDOZ)
MILES PHARMACEUTICAL DIV MILES INC (MILES)	BAYER CORPORATION (BAYER)
PENNEX PHARMACEUTICALS INC (PENNEX)	MORTON GROVE PHARMACEUTICALS INC (MORTON GROVE)
TAP PHARMACEUTICALS INC (TAP PHARMS)	TAP HOLDINGS INC (TAP HOLDINGS)

1.4 AVAILABILITY OF THE PUBLICATION AND UPDATING PROCEDURES

The *Approved Drug Products with Therapeutic Equivalence Evaluations* (Prescription Drug Products, OTC Drug Products and the Discontinued Drug Product Lists) is now available on diskette, on a quarterly basis, from the National Technical Information Service. The telephone number for the Subscription Department is (703) 487-6430. Written inquiries regarding this subscription may be forwarded to 5285 Port Royal Road Springfield, VA 22161.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1994) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1994	MAR 1995	JUN 1995	SEP 1995
DRUG PRODUCTS LISTED	9141	9195		
SINGLE SOURCE	2178 (23.8%)	2186 (23.8%)		
MULTISOURCE	6963 (76.2%)	7009 (76.2%)		
THERAPEUTICALLY EQUIVALENT	6330 (69.2%)	6380 (69.4%)		
NOT THERAPEUTICALLY EQUIVALENT	453 (5.0%)	453 (4.9%)		
EXCEPTIONS[1]	180 (2.0%)	176 (1.9%)		
NEW MOLECULAR ENTITIES APPROVED	--			
NUMBER OF APPLICANTS	534	541		

[1]Amino acid-containing products of varying composition (see Introduction, page xvii of the List).

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

		ACEBUTOLOL HCL				
AB		MYLAN	**EQ 200MG BASE**	**N74288 001**		
				APR 24, 1995		
AB			**EQ 400MG BASE**	**N74288 002**		
				APR 24, 1995		
		SECTRAL				
AB		WYETH AYERST	**EQ 200MG BASE**	**N18917 001**		
				DEC 28, 1984		
AB	+		**EQ 400MG BASE**	**N18917 003**		
				DEC 28, 1984		

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

			ACETAMINOPHEN AND CODEINE PHOSPHATE				
> DLT >	**AA**		KV PHARM	**300MG;30MG**	**N85288 001**		
> DLT >	**AA**			**300MG;60MG**	**N85365 001**		
> DLT >				325MG;15MG	N85364 001		
> DLT >				325MG;45MG	N85363 001		
> ADD >		@		300MG;30MG	N85288 001		
> ADD >		@		300MG;60MG	N85365 001		
> ADD >		@		325MG;15MG	N85364 001		
> ADD >		@		325MG;45MG	N85363 001		
	AA		MIKART	**650MG;30MG**	**N89231 001**		
					MAR 03, 1986	> ADD >	
		+		650MG;30MG	N89231 001	> ADD >	
					MAR 03, 1986	> ADD >	
			PHENAPHEN-650 W/ CODEINE				
	AA	+	ROBINS AH	**650MG;30MG**	**N85856 001**		
		@		650MG;30MG	N85856 001		

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

		ANEXSIA				
AA		BOEHRINGER MANNHEIM	**500MG;5MG**	**N89160 001**		
				APR 23, 1987	> DLT >	
AA		KING PHARMS	**500MG;5MG**	**N89160 001**	> DLT >	
				APR 23, 1987	> ADD >	
					> ADD >	
		ANEXSIA 7.5/650				
AA		BOEHRINGER MANNHEIM	**650MG;7.5MG**	**N89725 001**	> DLT >	
				SEP 30, 1987	> DLT >	
AA		KING PHARMS	**650MG;7.5MG**	**N89725 001**	> ADD >	
				SEP 30, 1987	> ADD >	

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

		ACETAZOLAMIDE SODIUM		
AP		BEDFORD	**EQ 500MG BASE/VIAL**	**N40089 001**
				FEB 28, 1995
		DIAMOX		
AP	+	STORZ OPHTHALM	**EQ 500MG BASE/VIAL**	**N09388 001**
				DEC 05, 1990

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

		ACETYLCYSTEINE		
AN		DUPONT MERCK	**10%**	**N71364 001**
				MAY 01, 1989
AN			**20%**	**N71365 001**
				MAY 01, 1989
AN		FAULDING	**10%**	**N71364 001**
				MAY 01, 1989
AN			**20%**	**N71365 001**
				MAY 01, 1989

ADENOSINE

INJECTABLE; INJECTION

		ADENOSCAN		
	+	MEDCO RES	3MG/ML	N20059 001
				MAY 18, 1995

AMIKACIN SULFATE

INJECTABLE; INJECTION

		AMIKACIN			
AP		DUPONT MERCK	**EQ 50MG BASE/ML**	**N63350 001**	
				JUL 30, 1993	
AP			**EQ 250MG BASE/ML**	**N63350 002**	
				JUL 30, 1993	
AP	+	ELKINS SINN	**EQ 50MG BASE/ML**	**N63274 001**	
				MAY 18, 1992	
AP			**EQ 50MG BASE/ML**	**N63274 001**	
				MAY 18, 1992	
AP	+		**EQ 250MG BASE/ML**	**N63275 001**	
				MAY 18, 1992	
AP			**EQ 250MG BASE/ML**	**N63275 001**	
				MAY 18, 1992	

AMIKACIN SULFATE

INJECTABLE; INJECTION

		AMIKACIN		
	AP	FAULDING	**EQ 50MG BASE/ML**	**N63350 001**
				JUL 30, 1993
	AP		**EQ 250MG BASE/ML**	**N63350 002**
				JUL 30, 1993
		AMIKIN		
> DLT >	**AP**	APOTHECON	**EQ 50MG BASE/ML**	**N62311 001**
> ADD >	**AP**	+	**EQ 50MG BASE/ML**	**N62311 001**
> DLT >	**AP**		**EQ 250MG BASE/ML**	**N62311 002**
> ADD >	**AP**	+	**EQ 250MG BASE/ML**	**N62311 002**
> ADD >		@	EQ 50MG BASE/ML	N62562 001
> ADD >				SEP 20, 1984
> ADD >		@	EQ 250MG BASE/ML	N62562 002
> ADD >				SEP 20, 1984
> DLT >		@ BRISTOL	EQ 50MG BASE/ML	N62562 001
> DLT >				SEP 20, 1984
> DLT >		@	EQ 250MG BASE/ML	N62562 002
> DLT >				SEP 20, 1984

AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

> ADD >	@ APOTHECON	EQ 5MG BASE/ML	N50618 002
> ADD >			NOV 30, 1987
> ADD >	@	EQ 10MG BASE/ML	N50618 001
> ADD >			NOV 30, 1987
> DLT >	@ BRISTOL	EQ 5MG BASE/ML	N50618 002
> DLT >			NOV 30, 1987
> DLT >	@	EQ 10MG BASE/ML	N50618 001
> DLT >			NOV 30, 1987

AMINOPHYLLINE

INJECTABLE; INJECTION

		AMINOPHYLLINE		
> DLT >	**AP**	FUJISAWA	**25MG/ML**	**N88407 001**
> DLT >				JAN 25, 1984
> ADD >		@	25MG/ML	N88407 001
> ADD >				JAN 25, 1984

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

		AMITRIPTYLINE HCL		
	AB	ROXANE	**150MG**	**N86090 001**
		@	150MG	N86090 001

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

		LOTREL		
		CIBA GEIGY	EQ 2.5MG BASE;10MG	N20364 002
				MAR 03, 1995
			EQ 5MG BASE;10MG	N20364 003
				MAR 03, 1995
	+		EQ 5MG BASE;20MG	N20364 004
				MAR 03, 1995

AMOXICILLIN

CAPSULE; ORAL

		AMOXICILLIN		
	AB	CONSOLIDATED PHARM	**250MG**	**N62058 001**
	AB		**500MG**	**N62058 002**
		COMOX		
	AB	COPANOS	**250MG**	**N62058 001**
	AB		**500MG**	**N62058 002**
> DLT >		**POLYMOX**		
> DLT >	**AB**	APOTHECON	**250MG**	**N63099 001**
> DLT >				MAR 20, 1992
> DLT >	**AB**		**500MG**	**N63099 002**
> DLT >				MAR 20, 1992
> ADD >		**TRIMOX**		
> ADD >	**AB**	APOTHECON	**250MG**	**N63099 001**
> ADD >				MAR 20, 1992
> ADD >	**AB**		**500MG**	**N63099 002**
> ADD >				MAR 20, 1992

POWDER FOR RECONSTITUTION; ORAL

		AMOXICILLIN		
	AB	CONSOLIDATED PHARM	**125MG/5ML**	**N62059 001**
	AB		**250MG/5ML**	**N62059 002**
		AMOXICILLIN TRIHYDRATE		
	AB	COPANOS	**125MG/5ML**	**N62059 001**
	AB		**250MG/5ML**	**N62059 002**

AMPHOTERICIN B

INJECTABLE; INJECTION

		AMPHOTERICIN B		
	AP	GENSIA	**50MG/VIAL**	**N64062 001**
				MAR 31, 1995

AMPICILLIN SODIUM

INJECTABLE; INJECTION
AMPICILLIN SODIUM

@	CONSOLIDATED PHARM	EQ 125MG BASE/VIAL	N61936 005	
@		EQ 250MG BASE/VIAL	N61936 001	
@		EQ 500MG BASE/VIAL	N61936 002	
@		EQ 1GM BASE/VIAL	N61936 003	
@		EQ 2GM BASE/VIAL	N61936 004	
@	COPANOS	EQ 125MG BASE/VIAL	N61936 005	
@		EQ 250MG BASE/VIAL	N61936 001	
@		EQ 500MG BASE/VIAL	N61936 002	
@		EQ 1GM BASE/VIAL	N61936 003	
@		EQ 2GM BASE/VIAL	N61936 004	

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL
AMPICILLIN TRIHYDRATE

AB	CONSOLIDATED PHARM	EQ 250MG BASE	N61602 001	
AB		EQ 500MG BASE	N61602 002	
AB	COPANOS	EQ 250MG BASE	N61602 001	
AB		EQ 500MG BASE	N61602 002	

POWDER FOR RECONSTITUTION; ORAL
AMPICILLIN TRIHYDRATE

AB	CONSOLIDATED PHARM	EQ 125MG BASE/5ML	N61601 001	
AB		EQ 250MG BASE/5ML	N61601 002	
AB	COPANOS	EQ 125MG BASE/5ML	N61601 001	
AB		EQ 250MG BASE/5ML	N61601 002	
	POLYCILLIN			
> DLT > AB	+ BRISTOL	EQ 500MG BASE/5ML	N50308 003	
> ADD >	+	EQ 500MG BASE/5ML	N50308 003	

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
VASOCON-A

> DLT >	+ CIBA VISION	0.5%;0.05%	N18746 001	APR 30, 1990

ASPIRIN; METHOCARBAMOL

TABLET; ORAL
METHOCARBAMOL AND ASPIRIN

AB	STEVENS J	325MG;400MG	N81145 001	JAN 31, 1995

ATENOLOL

TABLET; ORAL
ATENOLOL

AB	COPLEY PHARM	50MG	N74120 001	FEB 24, 1995
AB		100MG	N74120 002	FEB 24, 1995
AB	LEMMON	50MG	N74056 001	JAN 18, 1995
AB		100MG	N74056 002	JAN 18, 1995
AB	MARTEC	50MG	N74127 001	FEB 21, 1995
AB		100MG	N74127 002	FEB 21, 1995

ATOVAQUONE

SUSPENSION; ORAL
MEPRON

	+ BURROUGHS WELLCOME	750MG/5ML	N20500 001	FEB 08, 1995

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION
AZATHIOPRINE SODIUM

AP	BEDFORD	EQ 100MG BASE/VIAL	N74419 001	MAR 31, 1995

IMURAN

AP	+ BURROUGHS WELLCOME	EQ 100MG BASE/VIAL	N17391 001	

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT	ADV REMEDIES	500 UNITS/GM; 10,000 UNITS/GM	N64028 001	JAN 30, 1995
AT	BAUSCH AND LOMB	500 UNITS/GM; 10,000 UNITS/GM	N64046 001	JAN 26, 1995

POLYSPORIN

AT	+ BURROUGHS WELLCOME	500 UNITS/GM; 10,000 UNITS/GM	N61229 001	

BENDROFLUMETHIAZIDE

TABLET; ORAL

		NATURETIN-10			
> ADD >	+	APOTHECON	10MG	N12164 003	
> DLT >	+	SQUIBB	10MG	N12164 003	
		NATURETIN-2.5			
> ADD >	@	APOTHECON	2.5MG	N12164 001	
> DLT >	@	SQUIBB	2.5MG	N12164 001	
		NATURETIN-5			
> ADD >		APOTHECON	5MG	N12164 002	
> DLT >		SQUIBB	5MG	N12164 002	

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

	BRETYLOL			
AP	DUPONT MERCK	50MG/ML	N17954 001	
AP	FAULDING	50MG/ML	N17954 001	

BUMETANIDE

INJECTABLE; INJECTION

	BUMETANIDE			
AP	BEDFORD	0.25MG/ML	N74441 001	JAN 27, 1995

TABLET; ORAL

	BUMETANIDE			
AB	ZENITH LABS	0.5MG	N74225 001	APR 24, 1995
AB		1MG	N74225 002	APR 24, 1995
AB		2MG	N74225 003	APR 24, 1995
	BUMEX			
AB	ROCHE	0.5MG	N18225 002	FEB 28, 1983
AB		1MG	N18225 001	FEB 28, 1983
AB	+	2MG	N18225 003	JUN 14, 1985

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

		MARCAINE HCL				
> ADD >	AP	+ SANOFI WINTHROP	0.25%	N16964 001		
> ADD >	AP	+	0.5%	N16964 006		
> ADD >	AP	+	0.75%	N16964 009		
> DLT >	AP	+ STERLING WINTHROP	0.25%	N16964 001		
> DLT >	AP	+	0.5%	N16964 006		
> DLT >	AP	+	0.75%	N16964 009		

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

		MARCAINE HCL W/ EPINEPHRINE				
> ADD >	AP	+ SANOFI WINTHROP	0.25%;0.0091MG/ML	N16964 004		
> ADD >	AP	+	0.5%;0.0091MG/ML	N16964 008		
> ADD >	AP	+	0.75%;0.0091MG/ML	N16964 010		
> DLT >	AP	+ STERLING WINTHROP	0.25%;0.0091MG/ML	N16964 004		
> DLT >	AP	+	0.5%;0.0091MG/ML	N16964 008		
> DLT >	AP	+	0.75%;0.0091MG/ML	N16964 010		

CALCITONIN, SALMON

INJECTABLE; INJECTION

	CALCITONIN-SALMON			
AP	ASTRA	200 IU/ML	N73690 001	APR 14, 1995

CAPTOPRIL

TABLET; ORAL

	CAPOTEN			
AB	BRISTOL MYERS SQUIBB	12.5MG	N18343 005	JAN 17, 1985
AB		25MG	N18343 002	
AB		50MG	N18343 001	
AB	+	100MG	N18343 003	
	CAPTOPRIL			
AB	APOTHECON	12.5MG	N74472 001	MAR 31, 1995
AB		25MG	N74472 002	MAR 31, 1995
AB		50MG	N74472 003	MAR 31, 1995

CAPTOPRIL

TABLET; ORAL

	CAPTOPRIL				
AB	APOTHECON	100MG	N74472 004		
			MAR 31, 1995		

CARBACHOL

SOLUTION; INTRAOCULAR

	CARBASTAT				
AT	CIBA	0.01%	N73677 001		
			APR 28, 1995		
	MIOSTAT				
AT	+ ALCON	0.01%	N16968 001		

CEFACLOR

CAPSULE; ORAL

	CECLOR				
AB	+ LILLY	EQ 250MG BASE	N50521 001		
AB		EQ 250MG BASE	N62205 001		
AB	+	EQ 500MG BASE	N50521 002	> DLT >	
AB		EQ 500MG BASE	N62205 002	> ADD >	
	CEFACLOR				
AB	LEDERLE	EQ 250MG BASE	N64107 001		
			APR 27, 1995		
AB		EQ 500MG BASE	N64107 002		
			APR 27, 1995		
AB	ZENITH LABS	EQ 250MG BASE	N64061 001		
			APR 27, 1995		
AB		EQ 500MG BASE	N64061 002		
			APR 27, 1995		

POWDER FOR RECONSTITUTION; ORAL

	CECLOR				
AB	+ LILLY	EQ 125MG BASE/5ML	N50522 001		
AB		EQ 125MG BASE/5ML	N62206 001		
AB	+	EQ 187MG BASE/5ML	N62206 003		
			APR 20, 1988		
AB	+	EQ 250MG BASE/5ML	N50522 002		
AB		EQ 250MG BASE/5ML	N62206 002		
AB	+	EQ 375MG BASE/5ML	N62206 004		
			APR 20, 1988		
	CEFACLOR				
AB	LEDERLE	EQ 125MG BASE/5ML	N64114 001		
			APR 28, 1995		

CEFACLOR

POWDER FOR RECONSTITUTION; ORAL

	CEFACLOR		
AB	LEDERLE	EQ 187MG BASE/5ML	N64115 001
			APR 28, 1995
AB		EQ 250MG BASE/5ML	N64116 001
			APR 28, 1995
AB		EQ 375MG BASE/5ML	N64110 001
			APR 28, 1995
AB	ZENITH LABS	EQ 125MG BASE/5ML	N64087 001
			APR 28, 1995
AB		EQ 187MG BASE/5ML	N64086 001
			APR 28, 1995
AB		EQ 250MG BASE/5ML	N64085 001
			APR 28, 1995
AB		EQ 375MG BASE/5ML	N64070 001
			APR 28, 1995

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION

	MANDOL		
	+ LILLY	EQ 500MG BASE/VIAL	N50504 001
	@	EQ 500MG BASE/VIAL	N50504 001

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

	CEFAZOLIN SODIUM		
AP	ELKINS SINN	EQ 250MG BASE/VIAL	N62807 001
			JAN 12, 1988
AP		EQ 500MG BASE/VIAL	N62807 002
			JAN 12, 1988
AP		EQ 1GM BASE/VIAL	N62807 003
			JAN 12, 1988
AP		EQ 5GM BASE/VIAL	N62807 004
			JAN 12, 1988
AP		EQ 10GM BASE/VIAL	N62807 005
			JAN 12, 1988
AP		EQ 20GM BASE/VIAL	N62807 006
			JAN 12, 1988
	@	EQ 250MG BASE/VIAL	N62807 001
			JAN 12, 1988
	@	EQ 500MG BASE/VIAL	N62807 002
			JAN 12, 1988

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

@	ELKINS SINN	EQ 1GM BASE/VIAL	N62807 003 JAN 12, 1988
@		EQ 5GM BASE/VIAL	N62807 004 JAN 12, 1988
@		EQ 10GM BASE/VIAL	N62807 005 JAN 12, 1988
@		EQ 20GM BASE/VIAL	N62807 006 JAN 12, 1988

CEFOPERAZONE SODIUM

INJECTABLE; INJECTION
CEFOBID

	PFIZER	EQ 1GM BASE/VIAL	N63333 001 MAR 31, 1995
		EQ 2GM BASE/VIAL	N63333 002 MAR 31, 1995

CEFORANIDE

INJECTABLE; INJECTION
PRECEF

>ADD>	APOTHECON	500MG/VIAL	N62579 001 NOV 26, 1984	
>ADD>		1GM/VIAL	N62579 002 NOV 26, 1984	
>ADD>		2GM/VIAL	N62579 003 NOV 26, 1984	
>ADD>		10GM/VIAL	N62579 004 NOV 26, 1984	
>ADD>		20GM/VIAL	N62579 005 NOV 26, 1984	
>DLT>	~~BRISTOL~~	~~500MG/VIAL~~	~~N62579 001 NOV 26, 1984~~	
>DLT>		~~1GM/VIAL~~	~~N62579 002 NOV 26, 1984~~	
>DLT>		~~2GM/VIAL~~	~~N62579 003 NOV 26, 1984~~	
>DLT>		~~10GM/VIAL~~	~~N62579 004 NOV 26, 1984~~	
>DLT>		~~20GM/VIAL~~	~~N62579 005 NOV 26, 1984~~	

CEFOXITIN SODIUM

INJECTABLE; INJECTION
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	MERCK SHARP DOHME	EQ 20MG BASE/ML	N50581 002 SEP 20, 1984	
+		EQ 40MG BASE/ML	N50581 001 SEP 20, 1984	
@		EQ 20MG BASE/ML	N50581 002 SEP 20, 1984	
@		EQ 40MG BASE/ML	N50581 001 SEP 20, 1984	

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION
ROCEPHIN

AP	+ ROCHE	**EQ 250MG BASE/VIAL**	**N50585 001 DEC 21, 1984**	
AP	+	**EQ 500MG BASE/VIAL**	**N50585 002 DEC 21, 1984**	
AP	+	**EQ 1GM BASE/VIAL**	**N50585 003 DEC 21, 1984**	
	+	EQ 250MG BASE/VIAL	N50585 001 DEC 21, 1984	
	+	EQ 500MG BASE/VIAL	N50585 002 DEC 21, 1984	
	+	EQ 1GM BASE/VIAL	N50585 003 DEC 21, 1984	

CEFUROXIME SODIUM

INJECTABLE; INJECTION
KEFUROX

>DLT> **AP**	+ LILLY	**EQ 7.5GM BASE/VIAL**	**N62591 003 DEC 17, 1987**	
>ADD> **AP**		**EQ 7.5GM BASE/VIAL**	**N62591 003 DEC 17, 1987**	

ZINACEF

>DLT> **AP**	GLAXO	**EQ 7.5GM BASE/VIAL**	**N50558 004 OCT 23, 1986**	
>ADD> **AP**	+	**EQ 7.5GM BASE/VIAL**	**N50558 004 OCT 23, 1986**	

CEPHALEXIN

POWDER FOR RECONSTITUTION; ORAL

CEPHALEXIN

> ADD >	**AB**	APOTHECON	**EQ 125MG BASE/5ML**	**N62986 001**	
> ADD >				APR 18, 1991	
> ADD >	**AB**		**EQ 250MG BASE/5ML**	**N62987 001**	
> ADD >				JUL 25, 1989	
> DLT >	**AB**	SQUIBB MARK	**EQ 125MG BASE/5ML**	**N62986 001**	
> DLT >				APR 18, 1991	
> DLT >	**AB**		**EQ 250MG BASE/5ML**	**N62987 001**	
> DLT >				JUL 25, 1989	

CEPHRADINE

CAPSULE; ORAL

VELOSEF

> ADD >	**AB**	+ APOTHECON	**250MG**	**N61764 001**	
> ADD >	**AB**	+	**500MG**	**N61764 002**	
> DLT >	**AB**	+ ERSANA	**250MG**	**N61764 001**	
> DLT >	**AB**	+	**500MG**	**N61764 002**	

INJECTABLE; INJECTION

VELOSEF

> ADD >	+ APOTHECON	250MG/VIAL	N61976 001	
> ADD >	+	500MG/VIAL	N61976 002	
> ADD >	+	1GM/VIAL	N61976 004	
> ADD >	+	2GM/VIAL	N61976 003	
> ADD >	+	4GM/VIAL	N61976 005	
> DLT >	+ SQUIBB	250MG/VIAL	N61976 001	
> DLT >	+	500MG/VIAL	N61976 002	
> DLT >	+	1GM/VIAL	N61976 004	
> DLT >	+	2GM/VIAL	N61976 003	
> DLT >	+	4GM/VIAL	N61976 005	

POWDER FOR RECONSTITUTION; ORAL

VELOSEF '125'

> ADD >	**AB**	+ APOTHECON	**125MG/5ML**	**N61763 001**	
> DLT >	**AB**	+ ERSANA	**125MG/5ML**	**N61763 001**	

VELOSEF '250'

> ADD >	**AB**	+ APOTHECON	**250MG/5ML**	**N61763 002**	
> DLT >	**AB**	+ ERSANA	**250MG/5ML**	**N61763 002**	

CHLORAMPHENICOL

CAPSULE; ORAL

MYCHEL

AB	ARMENPHARM	**250MG**	**N60851 001**	

CHLORAMPHENICOL

CAPSULE; ORAL

MYCHEL

AB	RACHELLE	**250MG**	**N60851 001**	

CHLORPHENIRAMINE MALEATE

INJECTABLE; INJECTION

CHLORPHENIRAMINE MALEATE

AP	STERIS	**10MG/ML**	**N83593 001**	
> DLT >		100MG/ML	N86095 001	
	@	10MG/ML	N83593 001	
> ADD >	@	100MG/ML	N86095 001	

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLORPROMAZINE HCL

AP	STERIS	**25MG/ML**	**N85591 001**	
	@	25MG/ML	N85591 001	

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

AB	LEMMON	**100MG**	**N88768 001**	
			OCT 11, 1984	
	@	100MG	N88768 001	
			OCT 11, 1984	

GLUCAMIDE

AB	LEMMON	**250MG**	**N88641 001**	
			OCT 11, 1984	
	@	250MG	N88641 001	
			OCT 11, 1984	

CHOLESTYRAMINE

BAR, CHEWABLE; ORAL

CHOLYBAR

+ PARKE DAVIS	EQ 4GM RESIN/BAR	N71621 001	
		MAY 26, 1988	
	EQ 4GM RESIN/BAR	N71739 001	
		MAY 26, 1988	

CHOLESTYRAMINE

BAR, CHEWABLE; ORAL
CHOLYBAR
@ PARKE DAVIS — EQ 4GM RESIN/BAR — N71621 001 MAY 26, 1988
@ — EQ 4GM RESIN/BAR — N71739 001 MAY 26, 1988

TABLET; ORAL
QUESTRAN
+ BRISTOL MYERS SQUIBB — EQ 1GM RESIN — N73403 001 APR 28, 1994
@ — EQ 1GM RESIN — N73403 001 APR 28, 1994

CIMETIDINE

TABLET; ORAL
CIMETIDINE

AB	GENEVA PHARMS	200MG	N74100 001	JAN 31, 1995
AB		300MG	N74100 002	JAN 31, 1995
AB		400MG	N74100 003	JAN 31, 1995
AB		800MG	N74100 004	JAN 31, 1995
AB	LEMMON	200MG	N74365 001	FEB 28, 1995
AB		300MG	N74365 002	FEB 28, 1995
AB		400MG	N74365 003	FEB 28, 1995
AB		800MG	N74365 004	FEB 28, 1995
> ADD > AB	ZENITH LABS	200MG	N74401 001	MAY 30, 1995
> ADD > AB		300MG	N74401 002	MAY 30, 1995
> ADD > AB		400MG	N74401 003	MAY 30, 1995
> ADD > AB		800MG	N74402 001	MAY 30, 1995

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
CIMETIDINE HCL

AP	ABBOTT	EQ 300MG BASE/2ML	N74344 001	JAN 31, 1995
AP		EQ 300MG BASE/2ML	N74345 001	JAN 31, 1995
AP		EQ 300MG BASE/2ML	N74422 001	JAN 31, 1995

CLINDAMYCIN PHOSPHATE

SOLUTION; TOPICAL
CLEOCIN
UPJOHN — EQ 1% BASE — N50537 002 FEB 22, 1994

SWAB; TOPICAL
CLEOCIN
UPJOHN — EQ 1% BASE — N50537 002 FEB 22, 1994

CLOBETASOL PROPIONATE

OINTMENT; TOPICAL
EMBELINE
AB DPT — 0.05% — N74221 001 MAR 31, 1995

CLOTRIMAZOLE

SOLUTION; TOPICAL
CLOTRIMAZOLE
AT LEMMON — 1% — N73306 001 FEB 28, 1995

CORTICOTROPIN

INJECTABLE; INJECTION
ACTH
AP PARKE DAVIS — 40 UNITS/VIAL — N08317 004
@ — 40 UNITS/VIAL — N08317 004

CROMOLYN SODIUM

SOLUTION/DROPS; OPHTHALMIC

		CROLOM			
AT		BAUSCH AND LOMB	4%	N74443 001	
				JAN 30, 1995	
		OPTICROM			
AT	+	FISONS	4%	N18155 001	
				OCT 03, 1984	

CYANOCOBALAMIN

INJECTABLE; INJECTION

	CYANOCOBALAMIN			
	@ WARNER CHILCOTT	1MG/ML	N07085 002	
	RUBRAMIN PC			
AP	+ SQUIBB	0.1MG/ML	N06799 002	
	@	0.1MG/ML	N06799 002	
	SYTOBEX			
AP	PARKE DAVIS	1MG/ML	N07085 002	

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

		CYCLOBENZAPRINE HCL			
> ADD >	AB	BARR	10MG	N73541 001	
> ADD >				MAY 23, 1995	

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

		CYPROHEPTADINE HCL			
> DLT >	AA	ASCOT	4MG	N87685 001	
> DLT >				OCT 25, 1982	
> ADD >		@	4MG	N87685 001	
> ADD >				OCT 25, 1982	

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

	DAUNORUBICIN HCL			
AP	CETUS BEN VENUE	EQ 20MG BASE/VIAL	N64103 001	
			FEB 03, 1995	

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

	DDAVP			
	+ RHONE POULENC RORER	0.015MG/ML	N18938 002	
			APR 25, 1995	

SPRAY, METERED; NASAL

	DESMOPRESSIN ACETATE			
	+ RHONE POULENC RORER	0.15MG/INH	N20355 001	
			MAR 07, 1994	
	STIMATE			
	+ RHONE POULENC RORER	0.15MG/INH	N20355 001	
			MAR 07, 1994	

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21

		DESOGEN			
AB	+	ORGANON	0.15MG;0.03MG	N20071 001	
				DEC 10, 1992	
		@	0.15MG;0.03MG	N20071 001	
				DEC 10, 1992	
		ORTHO-CEPT			
AB		JOHNSON RW	0.15MG;0.03MG	N20301 001	
				DEC 14, 1992	
			0.15MG;0.03MG	N20301 001	
				DEC 14, 1992	

DEXAMETHASONE

AEROSOL; TOPICAL

		DECASPRAY			
> DLT >		+ MERCK SHARP DOHME	0.4%	N12731 002	
> ADD >		+	0.04%	N12731 002	

TABLET; ORAL

	HEXADROL			
BP	ORGANON	0.5MG	N12675 004	
BP		0.75MG	N12675 007	
BP		1.5MG	N12675 009	
	@	0.5MG	N12675 004	
	@	0.75MG	N12675 007	
	@	1.5MG	N12675 009	

> ADD > DEXRAZOXANE HYDROCHLORIDE

> ADD > INJECTABLE; INJECTION
> ADD > ZINECARD
> ADD > + PHARMACIA EQ 250MG BASE/VIAL N20212 001
> ADD > MAY 26, 1995
> ADD > + EQ 500MG BASE/VIAL N20212 002
> ADD > MAY 26, 1995

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 2.5% IN PLASTIC CONTAINER
MCGAW 2.5GM/100ML N19626 001
FEB 02, 1988
@ 2.5GM/100ML N19626 001
FEB 02, 1988

DEXTROSE 7.7% IN PLASTIC CONTAINER
MCGAW 7.7GM/100ML N19626 003
FEB 02, 1988
@ 7.7GM/100ML N19626 003
FEB 02, 1988

DIAZEPAM

INJECTABLE; INJECTION
DIAZEPAM
AP FUJISAWA **5MG/ML** **N70662 001**
JUN 25, 1986
@ 5MG/ML N70662 001
JUN 25, 1986

DICLOFENAC POTASSIUM

TABLET; ORAL
CATAFLAM
GEIGY 25MG N20142 001
NOV 24, 1993
@ 25MG N20142 001
NOV 24, 1993

DILTIAZEM HYDROCHLORIDE

TABLET; ORAL
DILTIAZEM HCL
> ADD > **AB** LEMMON **30MG** **N74185 001**
> ADD > MAY 31, 1995
> ADD > **AB** **60MG** **N74185 002**
> ADD > MAY 31, 1995
> ADD > **AB** **90MG** **N74185 003**
> ADD > MAY 31, 1995
> ADD > **AB** **120MG** **N74185 004**
> ADD > MAY 31, 1995
AB ZENITH LABS **30MG** **N74168 001**
MAR 03, 1995
AB **60MG** **N74168 002**
MAR 03, 1995
AB **90MG** **N74168 003**
MAR 03, 1995
AB **120MG** **N74168 004**
MAR 03, 1995

DIMENHYDRINATE

INJECTABLE; INJECTION
DIMENHYDRINATE
AP STERIS **50MG/ML** **N83531 001**
@ 50MG/ML N83531 001

DINOPROSTONE

INSERT, EXTENDED RELEASE; VAGINAL
CERVIDIL
+ CONTROLLED THERAP 10MG N20411 001
MAR 30, 1995

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HCL
> DLT > **AA** WEST WARD PHARM **50MG** **N83567 001**
> ADD > @ 50MG N83567 001

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

		DIPIVEFRIN HCL			
> ADD >	**AT**	BAUSCH AND LOMB	**0.1%**		**N74188 001**
> ADD >					MAY 19, 1995

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL

		DEPAKOTE			
> DLT >		+ ABBOTT	EQ 125MG BASE		N19680 001
> DLT >					SEP 12, 1989
> ADD >		+	EQ 125MG VALPROIC ACID		N19680 001
> ADD >					SEP 12, 1989

TABLET, DELAYED RELEASE; ORAL

		DEPAKOTE			
> DLT >		ABBOTT	EQ 125MG BASE		N18723 003
> DLT >					OCT 26, 1984
> DLT >			EQ 250MG BASE		N18723 001
> DLT >					MAR 10, 1983
> DLT >		+	EQ 500MG BASE	> DLT >	N18723 002
> DLT >				> DLT >	MAR 10, 1983
> ADD >			EQ 125MG VALPROIC ACID	> DLT >	N18723 003
> ADD >				> ADD >	OCT 26, 1984
> ADD >			EQ 250MG VALPROIC ACID	> ADD >	N18723 001
> ADD >				> ADD >	MAR 10, 1983
> ADD >		+	EQ 500MG VALPROIC ACID		N18723 002
> ADD >					MAR 10, 1983

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

		DOBUTAMINE HCL		
AP		ASTRA	**EQ 12.5MG BASE/ML**	**N74098 001**
				FEB 21, 1995
AP		SANOFI WINTHROP	**EQ 12.5MG BASE/ML**	**N74292 001**
				FEB 16, 1995

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

		INTROPIN		
AP	+	DUPONT MERCK	**40MG/ML**	**N17395 001**
AP	+		**80MG/ML**	**N17395 002**

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

		INTROPIN		
AP	+	DUPONT MERCK	**160MG/ML**	**N17395 003**
AP	+	FAULDING	**40MG/ML**	**N17395 001**
AP	+		**80MG/ML**	**N17395 002**
AP	+		**160MG/ML**	**N17395 003**

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

		DOXORUBICIN HCL		
AP		PHARMACHEMIE (NL)	**2MG/ML**	**N63336 001**
				FEB 28, 1995
AP			**200MG/100ML**	**N63336 004**
				FEB 28, 1995

DOXYCYCLINE

CAPSULE; ORAL

		DOXYCYCLINE MONOHYDRATE		
	+	VINTAGE PHARMS	EQ 100MG BASE	N50641 001
				DEC 29, 1989
		MONODOX		
	+	OCLASSEN	EQ 100MG BASE	N50641 001
				DEC 29, 1989

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

		DOXYCYCLINE HYCLATE		
AB		PVT FORM	**EQ 50MG BASE**	**N62631 001**
				JUL 24, 1986
AB			**EQ 100MG BASE**	**N62631 002**
				JUL 24, 1986
	@		EQ 50MG BASE	N62631 001
				JUL 24, 1986
	@		EQ 100MG BASE	N62631 002
				JUL 24, 1986

DROPERIDOL

INJECTABLE; INJECTION

	DROPERIDOL			
AP	DUPONT MERCK	2.5MG/ML	N71645 001	APR 07, 1988
AP	FAULDING	2.5MG/ML	N71645 001	APR 07, 1988

EDETATE DISODIUM

INJECTABLE; INJECTION

>_DLT_>	SODIUM VERSENATE			
>_DLT_>	+ 3M	200MG/ML	N10573 001	
>_ADD_>	@	200MG/ML	N10573 001	

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

	ERYC			
AB	+ PARKE DAVIS	250MG	N62338 001	
AB		250MG	N62618 001	SEP 25, 1985
AB	+	250MG	N62618 001	SEP 25, 1985
	@	250MG	N62338 001	

TABLET, DELAYED RELEASE; ORAL

	ROBINMYCIN			
AB	ROBINS AH	250MG	N61633 001	
	@	250MG	N61633 001	

ERYTHROMYCIN ESTOLATE

>_DLT_>	DROPS; ORAL			
>_DLT_>	ILOSONE			
>_DLT_>	+ DISTA	EQ 100MG BASE/ML	N61894 003	
>_ADD_>	SUSPENSION/DROPS; ORAL			
>_ADD_>	ILOSONE			
>_ADD_>	+ DISTA	EQ 100MG BASE/ML	N61894 003	

ERYTHROMYCIN ETHYLSUCCINATE

>_DLT_>	DROPS; ORAL			
>_DLT_>	PEDIAMYCIN			
>_DLT_>	+ ROSS LABS	EQ 100MG BASE/2.5ML	N62305 002	
	SUSPENSION; ORAL			
	WYAMYCIN E			
AB	WYETH AYERST	EQ 200MG BASE/5ML	N62123 002	
AB		EQ 400MG BASE/5ML	N62123 001	
	@	EQ 200MG BASE/5ML	N62123 002	
	@	EQ 400MG BASE/5ML	N62123 001	
>_ADD_>	SUSPENSION/DROPS; ORAL			
>_ADD_>	PEDIAMYCIN			
>_ADD_>	+ ROSS LABS	EQ 100MG BASE/2.5ML	N62305 002	

ERYTHROMYCIN STEARATE

TABLET; ORAL

	ETHRIL 250			
AB	SQUIBB	EQ 250MG BASE	N61605 001	
	@	EQ 250MG BASE	N61605 001	
	ETHRIL 500			
AB	SQUIBB	EQ 500MG BASE	N61605 002	
	@	EQ 500MG BASE	N61605 002	

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

	VIVELLE			
BX	CIBA GEIGY	0.05MG/24HR	N20323 002	OCT 28, 1994
BX		0.1MG/24HR	N20323 004	OCT 28, 1994
		0.0375MG/24HR	N20323 001	OCT 28, 1994
		0.075MG/24HR	N20323 003	OCT 28, 1994
BX	NOVEN	0.05MG/24HR	N20323 002	OCT 28, 1994
BX		0.1MG/24HR	N20323 004	OCT 28, 1994
		0.0375MG/24HR	N20323 001	OCT 28, 1994
		0.075MG/24HR	N20323 003	OCT 28, 1994

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
OVCON-35
+ BRISTOL MYERS SQUIBB 0.035MG;0.4MG N18127 001
+ MEAD JOHNSON 0.035MG;0.4MG N18127 001
OVCON-50
@ BRISTOL MYERS SQUIBB 0.05MG;1MG N18128 001
+ MEAD JOHNSON 0.05MG;1MG N18128 001

TABLET; ORAL-28
OVCON-35
BRISTOL MYERS SQUIBB 0.035MG;0.4MG N17716 001
MEAD JOHNSON 0.035MG;0.4MG N17716 001
OVCON-50
BRISTOL MYERS SQUIBB 0.05MG;1MG N17576 001
MEAD JOHNSON 0.05MG;1MG N17576 001

ETOPOSIDE

INJECTABLE; INJECTION
TOPOSAR
AP PHARMACIA **20MG/ML** **N74166 001**
FEB 27, 1995

FENOFIBRATE

CAPSULE; ORAL
LIPIDIL
+ LABS FOURNIER 100MG N19304 001
DEC 31, 1993
@ 100MG N19304 001
DEC 31, 1993

FLUDROCORTISONE ACETATE

TABLET; ORAL
FLORINEF
> ADD > + APOTHECON 0.1MG N10060 001
> DLT > + SQUIBB 0.1MG N10060 001

FLUNISOLIDE

SPRAY, METERED; NASAL
NASALIDE
BX + SYNTEX 0.025MG/INH N18148 001

FLUNISOLIDE

SPRAY, METERED; NASAL
NASAREL
BX + SYNTEX 0.025MG/INH N20409 001
MAR 08, 1995

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCINOLONE ACETONIDE
AT + HAMILTON PHARMA CA **0.01%** **N12787 004**
AT + **0.025%** **N12787 002**
AT + **0.025%** **N12787 005**
+ 0.2% N16161 002
SYNALAR
AT + SYNTEX **0.01%** **N12787 004**
AT + **0.025%** **N12787 002**
SYNALAR-HP
+ SYNTEX 0.2% N16161 002
SYNEMOL
AT + SYNTEX **0.025%** **N12787 005**

OINTMENT; TOPICAL
FLUOCINOLONE ACETONIDE
AT + HAMILTON PHARMA CA **0.025%** **N13960 001**
SYNALAR
AT + SYNTEX **0.025%** **N13960 001**

SOLUTION; TOPICAL
FLUOCINOLONE ACETONIDE
AT + HAMILTON PHARMA CA **0.01%** **N15296 001**
SYNALAR
AT + SYNTEX **0.01%** **N15296 001**

FLUOCINONIDE

CREAM; TOPICAL
FLUOCINONIDE
AB + HAMILTON PHARMA CA **0.05%** **N16908 002**
FLUOCINONIDE EMOLLIENT BASE
AB HAMILTON PHARMA CA **0.05%** **N16908 003**
LIDEX
AB + SYNTEX **0.05%** **N16908 002**
LIDEX-E
AB SYNTEX **0.05%** **N16908 003**

FLUOCINONIDE

GEL; TOPICAL
FLUOCINONIDE
AB + HAMILTON PHARMA CA 0.05% N17373 001
LIDEX
AB + SYNTEX 0.05% N17373 001

OINTMENT; TOPICAL
FLUOCINONIDE
AB + HAMILTON PHARMA CA 0.05% N16909 002
LIDEX
AB + SYNTEX 0.05% N16909 002

SOLUTION; TOPICAL
FLUOCINONIDE
AT FOUGERA 0.05% N72934 001
FEB 27, 1995
AT + HAMILTON PHARMA CA 0.05% N18849 001
APR 06, 1984
LIDEX
AT + SYNTEX 0.05% N18849 001
APR 06, 1984

FLURBIPROFEN

TABLET; ORAL
FLURBIPROFEN
> ADD > AB LEMMON 100MG N74431 001
> ADD > MAY 31, 1995
> ADD > AB NOVOPHARM 50MG N74405 002
> ADD > MAY 24, 1995
> ADD > AB 100MG N74405 001
> ADD > MAY 24, 1995
> ADD > AB ZENITH LABS 50MG N74411 001
> ADD > MAY 31, 1995
> ADD > AB 100MG N74411 002
> ADD > MAY 31, 1995

FLURBIPROFEN SODIUM

SOLUTION/DROPS; OPHTHALMIC
FLURBIPROFEN SODIUM
AT BAUSCH AND LOMB 0.03% N74447 001
JAN 04, 1995
OCUFEN
AT + ALLERGAN 0.03% N19404 001
DEC 31, 1986

FOSINOPRIL SODIUM

TABLET; ORAL
MONOPRIL
+ BRISTOL MYERS SQUIBB 20MG N19915 003
MAY 16, 1991
20MG N19915 003
MAY 16, 1991
+ 40MG N19915 004
MAR 28, 1995

GEMFIBROZIL

CAPSULE; ORAL
> DLT > **GEMFIBROZIL**
> DLT > AB + MYLAN 300MG N73466 001
> DLT > JAN 25, 1993
> ADD > @ 300MG N73466 001
> ADD > JAN 25, 1993
> DLT > AB PUREPAC PHARM 300MG N72929 001
> DLT > JAN 29, 1993
> ADD > @ 300MG N72929 001
> ADD > JAN 29, 1993
LOPID
AB + PARKE DAVIS 300MG N18422 002
@ 300MG N18422 002

TABLET; ORAL
GEMFIBROZIL
AB CHELSEA LABS 600MG N74442 001
APR 28, 1995
AB MYLAN 600MG N74452 001
FEB 16, 1995

GENTAMICIN SULFATE

SOLUTION/DROPS; OPHTHALMIC
GENTAMICIN SULFATE
AT ALCON EQ 0.3% BASE N62196 001

GLIPIZIDE

TABLET; ORAL
GLIPIZIDE
AB GENEVA PHARMS 5MG N74305 001
APR 07, 1995

GLIPIZIDE

TABLET; ORAL
GLIPIZIDE

	GENEVA PHARMS	10MG	N74305 002	APR 07, 1995
AB	WATSON LABS	**5MG**	**N74223 001**	FEB 27, 1995
AB		**10MG**	**N74223 002**	FEB 27, 1995

GLYBURIDE

TABLET; ORAL
GLUBATE

@	HOECHST ROUSSEL	1.5MG	N20055 001	APR 17, 1992
@		3MG	N20055 002	APR 17, 1992

GLYBURIDE (MICRONIZED)

AB	HOECHST ROUSSEL	**1.5MG**	**N20055 001**	APR 17, 1992
AB		**3MG**	**N20055 002**	APR 17, 1992

GLYNASE

AB	UPJOHN	**1.5MG**	**N20051 001**	MAR 04, 1992
AB		**3MG**	**N20051 002**	MAR 04, 1992

GLYCINE

SOLUTION; IRRIGATION
GLYCINE 1.5% IN PLASTIC CONTAINER

>DLT> >DLT>	**AT**	BAXTER	**1.5GM/100ML**	**N18522 001**	**FEB 19, 1982**
>ADD> >ADD>		@	1.5GM/100ML	N18522 001	FEB 19, 1982

GRANISETRON HYDROCHLORIDE

TABLET; ORAL
KYTRIL

+	SMITHKLINE BEECHAM	EQ 1MG BASE	N20305 001	MAR 16, 1995

GUANABENZ ACETATE

TABLET; ORAL
GUANABENZ ACETATE

AB	ZENITH LABS	**EQ 4MG BASE**	**N74149 001**	APR 07, 1995
		EQ 8MG BASE	N74149 002	APR 07, 1995

GUANFACINE HYDROCHLORIDE

TABLET; ORAL
TENEX

	ROBINS AH	1MG	N19032 001	OCT 27, 1986
+		2MG	N19032 002	NOV 07, 1988
@		3MG	N19032 003	NOV 07, 1988
		EQ 1MG BASE	N19032 001	OCT 27, 1986
+		EQ 2MG BASE	N19032 002	NOV 07, 1988
@		EQ 3MG BASE	N19032 003	NOV 07, 1988

HALCINONIDE

CREAM; TOPICAL
HALOG

>DLT>	**AT**	+ WESTWOOD SQUIBB	**0.1%**	**N17556 001**	
>ADD>		+	0.1%	N17556 001	

HALOG-E

>DLT>	**AT**	WESTWOOD SQUIBB	**0.1%**	**N18234 001**	
>ADD>			0.1%	N18234 001	

HEPARIN CALCIUM

INJECTABLE; INJECTION
CALCIPARINE

+	CHOAY	25,000 UNITS/ML	N18237 001
@	SANOFI WINTHROP	25,000 UNITS/ML	N18237 001

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN LOCK FLUSH

AP		SANOFI WINTHROP	10 UNITS/ML	N40082 001	FEB 28, 1995
AP			100 UNITS/ML	N40082 002	FEB 28, 1995

HEPARIN SODIUM

AP	+	ABBOTT	2,500 UNITS/ML	N05264 014	APR 07, 1986
	+		2,000 UNITS/ML	N05264 013	APR 07, 1986
AP		ELKINS SINN	10,000 UNITS/ML	N17037 013	APR 07, 1986
AP			5,000 UNITS/0.5ML	N17037 013	APR 07, 1986
AP		PHARMA SERVE NY	1,000 UNITS/ML	N86129 001	
AP		WYETH AYERST	2,500 UNITS/ML	N17007 007	
AP	+		2,500 UNITS/ML	N17007 007	

> DLT > HEPARIN SODIUM 1000 UNITS AND DEXTROSE 5% IN PLASTIC
> DLT > CONTAINER

> DLT > AP		MCGAW	200 UNITS/100ML	N19130 001	DEC 31, 1984
> ADD >	@		200 UNITS/100ML	N19130 001	DEC 31, 1984

> DLT > HEPARIN SODIUM 2000 UNITS IN DEXTROSE 5% IN PLASTIC
> DLT > CONTAINER

> DLT > AP		MCGAW	200 UNITS/100ML	N19130 003	DEC 31, 1984
> ADD >	@		200 UNITS/100ML	N19130 003	DEC 31, 1984

> DLT > HEPARIN SODIUM 5000 UNITS IN DEXTROSE 5% IN PLASTIC
> DLT > CONTAINER

> DLT > AP		MCGAW	1,000 UNITS/100ML	N19130 002	DEC 31, 1984
> ADD >	@		1,000 UNITS/100ML	N19130 002	DEC 31, 1984

HEPARIN SODIUM PRESERVATIVE FREE

AP	+	ABBOTT	2,500 UNITS/ML	N05264 014	APR 07, 1986
	+		2,000 UNITS/ML	N05264 013	APR 07, 1986
AP		FUJISAWA	1,000 UNITS/ML	N17029 010	APR 28, 1986
AP	+		1,000 UNITS/ML	N17029 010	APR 28, 1986
AP		PHARMA SERVE NY	1,000 UNITS/ML	N86129 001	

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM PRESERVATIVE FREE

AP		STERLING WINTHROP	10,000 UNITS/ML	N89522 001	MAY 04, 1987
AP	+		10,000 UNITS/ML	N89522 001	MAY 04, 1987

> DLT > LIQUAEMIN LOCK FLUSH

> DLT > AP		ORGANON	100 UNITS/ML	N00552 007	
> ADD >	@		100 UNITS/ML	N00552 007	

> DLT > LIQUAEMIN SODIUM

> DLT > AP		ORGANON	1,000 UNITS/ML	N00552 004	
> DLT > AP			5,000 UNITS/ML	N00552 003	
> DLT > AP			10,000 UNITS/ML	N00552 005	
> ADD >	@		1,000 UNITS/ML	N00552 004	
> ADD >	@		5,000 UNITS/ML	N00552 003	
> ADD >	@		10,000 UNITS/ML	N00552 005	

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL
> DLT > DRALZINE

> DLT > AA		LEMMON	25MG	N84301 001	
> ADD >	@		25MG	N84301 001	

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
APRESOLINE-ESIDRIX

	+	CIBA	25MG;15MG	N12026 002	
	@		25MG;15MG	N12026 002	

HYDROCHLOROTHIAZIDE

TABLET; ORAL
HYDROCHLOROTHIAZIDE

> DLT > AB		ASCOT	50MG	N87540 001	FEB 03, 1982
> ADD >	@		50MG	N87540 001	FEB 03, 1982

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL
HYZAAR
+ MERCK 12.5MG;50MG N20387 001 APR 28, 1995

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL
LOPRESSOR HCT
CIBA 25MG;50MG N18303 001 DEC 31, 1984
25MG;100MG N18303 002 DEC 31, 1984
+ 50MG;100MG N18303 003 DEC 31, 1984

LOPRESSOR HCT 100/25
CIBA 25MG;100MG N18303 002 DEC 31, 1984

LOPRESSOR HCT 100/50
+ CIBA 50MG;100MG N18303 003 DEC 31, 1984

LOPRESSOR HCT 50/25
CIBA 25MG;50MG N18303 001 DEC 31, 1984

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE
AB ZENITH LABS **25MG;50MG** **N74259 001** MAR 30, 1995

HYDROCORTISONE

CREAM; TOPICAL
HYDROCORTISONE
> DLT > **AT** CLAY PARK **1%** **N85026 001**
> ADD > @ 1% N85026 001

ENEMA; RECTAL
CORTENEMA
> DLT > **AT** **+** **100MG/60ML** **N16199 001**
> ADD > + SOLVAY 100MG/60ML N16199 001

HYDROCORTISONE

ENEMA; RECTAL
HYDROCORTISONE
> DLT > > DLT > **AT** COPLEY PHARM **100MG/60ML** **N74171 001** MAY 27, 1994
> DLT > > ADD > @ 100MG/60ML N74171 001 MAY 27, 1994
> ADD >

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROXYZINE HCL
AP PHARMAFAIR **50MG/ML** **N88881 001** FEB 14, 1986
@ 50MG/ML N88881 001 FEB 14, 1986
AP STERIS **25MG/ML** **N87274 001**
AP **50MG/ML** **N87274 002**
@ 25MG/ML N87274 001
@ 50MG/ML N87274 002

SYRUP; ORAL
HYDROXYZINE HCL
> DLT > **AA** BARRE **10MG/5ML** **N88785 001** FEB 03, 1988
> DLT > > ADD > @ 10MG/5ML N88785 001 FEB 03, 1988
> ADD >

IBUPROFEN

SUSPENSION; ORAL
CHILDREN'S MOTRIN
BX + MCNEIL CONS PRODS 100MG/5ML N19842 001 SEP 19, 1989

PEDIA PROFEN
BX **+** MCNEIL CONS PRODS **100MG/5ML** **N19842 001** SEP 19, 1989

SUSPENSION/DROPS; ORAL
MOTRIN
> ADD > > ADD > > ADD > > ADD > + MCNEIL CONS PRODS 40MG/ML N20476 001 MAY 25, 1995

> ADD > IOPROMIDE

> ADD > INJECTABLE; INJECTION
> ADD > ULTRAVIST
> ADD > + BERLEX EQ 150MG IODINE/ML N20220 004 MAY 10, 1995
> ADD > + EQ 240MG IODINE/ML N20220 003 MAY 10, 1995
> ADD > + EQ 300MG IODINE/ML N20220 002 MAY 10, 1995
> ADD > + EQ 370MG IODINE/ML N20220 001 MAY 10, 1995

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
ISOETHARINE HCL S/F
> DLT > AN + DEY 1% N89252 001 SEP 15, 1986
> DLT > @ 1% N89252 001 SEP 15, 1986
> ADD >

ISOFLURANE

LIQUID; INHALATION
ISOFLURANE
> ADD > AN MARSAM 99.9% N74393 001 MAY 12, 1995
> ADD >

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL
IMDUR
@ SCHERING 30MG N20225 001 AUG 12, 1993
+ 60MG N20225 002 AUG 12, 1993
+ 120MG N20225 003 MAR 30, 1995
@ SCHERING PLOUGH 30MG N20225 001 AUG 12, 1993
+ 60MG N20225 002 AUG 12, 1993

KANAMYCIN SULFATE

INJECTABLE; INJECTION
KANAMYCIN
AP ELKINS SINN EQ 75MG BASE/2ML N62324 001
AP EQ 500MG BASE/2ML N62324 002
AP EQ 1GM BASE/3ML N62324 003
@ EQ 75MG BASE/2ML N62324 001
@ EQ 500MG BASE/2ML N62324 002
@ EQ 1GM BASE/3ML N62324 003

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL
ORUVAIL
+ WYETH AYERST 100MG N19816 003 FEB 08, 1995
+ 150MG N19816 002 FEB 08, 1995

> ADD > LANSOPRAZOLE

> ADD > CAPSULE, DELAYED REL GRANULES; ORAL
> ADD > PREVACID
> ADD > TAP HOLDINGS 15MG N20406 001 MAY 10, 1995
> ADD > + 30MG N20406 002 MAY 10, 1995
> ADD >

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM
> ADD > + CETUS BEN VENUE EQ 200MG BASE/VIAL N40056 001 MAY 23, 1995
> ADD >

LEUPROLIDE ACETATE

INJECTABLE; INJECTION
LUPRON
+ TAP HOLDINGS 1MG/0.2ML N19010 001 APR 09, 1985
+ TAP PHARMS 5MG/ML N19010 001 APR 09, 1985

LINDANE

LOTION; TOPICAL

> DLT >		**SCABENE**				
> DLT >	**AT**	STIEFEL	**1%**	**N86769 001**		
> ADD >		@	1%	N86769 001		

SHAMPOO; TOPICAL

> DLT >		**SCABENE**				
> DLT >	**AT**	STIEFEL	**1%**	**N87940 001**		
> DLT >				APR 08, 1983		
> ADD >		@	1%	N87940 001		
> ADD >				APR 08, 1983		

LISINOPRIL

TABLET; ORAL

		PRINIVIL				
AB		MERCK	**2.5MG**	**N19558 006**		
				JAN 28, 1994		
			2.5MG	N19558 006		
				JAN 28, 1994		
		ZESTRIL				
AB		ZENECA	**2.5MG**	**N19777 005**		
				APR 29, 1993		
		@	2.5MG	N19777 005		
				APR 29, 1993		

LITHIUM CARBONATE

TABLET; ORAL

		LITHOTABS				
AB		SOLVAY	**300MG**	**N16980 001**		
AB	+		**300MG**	**N16980 001**		

LOSARTAN POTASSIUM

TABLET; ORAL

		COZAAR				
		MERCK	25MG	N20386 001		
				APR 14, 1995		
	+		50MG	N20386 002		
				APR 14, 1995		

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SOLUTION; IRRIGATION

		PHYSIOLYTE IN PLASTIC CONTAINER				
> DLT >	**AT**	MCGAW	**30MG/100ML;37MG/100ML;370MG/100ML;**			
> DLT >			**530MG/100ML;500MG/100ML**	**N19024 001**		
> DLT >				**JUN 08, 1984**		
> ADD >			30MG/100ML;37MG/100ML;370MG/100ML;			
> ADD >			530MG/100ML;500MG/100ML	N19024 001		
> ADD >				JUN 08, 1984		
		PHYSIOSOL IN PLASTIC CONTAINER				
> DLT >	**AT**	ABBOTT	**30MG/100ML;37MG/100ML;222MG/100ML;**			
> DLT >			**526MG/100ML;502MG/100ML**	**N17637 002**		
> DLT >				**JUL 08, 1982**		
> ADD >			30MG/100ML;37MG/100ML;222MG/100ML;			
> ADD >			526MG/100ML;502MG/100ML	N17637 002		
> ADD >				JUL 08, 1982		
> DLT >		**SYNOVALYTE IN PLASTIC CONTAINER**				
> DLT >	**AT**	BAXTER	**30MG/100ML;37MG/100ML;368MG/100ML;**			
> DLT >			**526MG/100ML;502MG/100ML**	**N19326 001**		
> DLT >				**JAN 25, 1985**		
> ADD >		@	30MG/100ML;37MG/100ML;368MG/100ML;			
> ADD >			526MG/100ML;502MG/100ML	N19326 001		
> ADD >				JAN 25, 1985		

MANNITOL

INJECTABLE; INJECTION

		MANNITOL 10%				
> DLT >	**AP**	ABBOTT	**10GM/100ML**	**N16269 002**		
> ADD >		@	10GM/100ML	N16269 002		
		MANNITOL 15%				
> DLT >	**AP**	ABBOTT	**15GM/100ML**	**N16269 003**		
> ADD >		@	15GM/100ML	N16269 003		
		MANNITOL 20%				
> DLT >	**AP**	ABBOTT	**20GM/100ML**	**N16269 004**		
> ADD >		@	20GM/100ML	N16269 004		
		MANNITOL 25%				
> DLT >	**AP**	ABBOTT	**12.5GM/50ML**	**N16269 005**		
> ADD >	**AP**		**12.5GM/50ML**	**N16269 006**		
> ADD >				AUG 25, 1994		
> ADD >		@	12.5GM/50ML	N16269 005		
		MANNITOL 5%				
> DLT >	**AP**	ABBOTT	**5GM/100ML**	**N16269 001**		
> ADD >		@	5GM/100ML	N16269 001		

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

	MEBENDAZOLE			
AB	COPLEY PHARM	**100MG**	**N73580 001**	JAN 04, 1995
	VERMOX			
AB	+ JANSSEN	**100MG**	**N17481 001**	

MEGESTROL ACETATE

TABLET; ORAL

	MEGACE			
AB	BRISTOL MYERS SQUIBB	**20MG**	**N16979 001**	
AB	+	**40MG**	**N16979 002**	
AB	MEAD JOHNSON	**20MG**	**N16979 001**	
AB	+	**40MG**	**N16979 002**	

METFORMIN HYDROCHLORIDE

TABLET; ORAL

	GLUCOPHAGE			
	BRISTOL MYERS SQUIBB	500MG	N20357 001	DEC 29, 1994
	+	850MG	N20357 002	DEC 29, 1994
	LIPHA	500MG	N20357 001	DEC 29, 1994
	+	850MG	N20357 002	DEC 29, 1994

METHADONE HYDROCHLORIDE

POWDER; FOR RX COMPOUNDING

METHADONE HCL			
MALLINCKRODT	50GM/BOT	N06383 002	
	100GM/BOT	N06383 003	
	500GM/BOT	N06383 004	

TABLET, DISPERSIBLE; ORAL

	METHADONE HCL			
AA	ROXANE	**40MG**	**N74081 001**	APR 28, 1995

METHOTRIMEPRAZINE

INJECTABLE; INJECTION

	LEVOPROME			
+	IMMUNEX	20MG/ML	N15865 001	
+	LEDERLE	20MG/ML	N15865 001	

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

	METHYLDOPATE HCL			
AP	DUPONT MERCK	**50MG/ML**	**N70691 001**	JUN 19, 1987
AP		**50MG/ML**	**N70849 001**	JUN 19, 1987
AP	FAULDING	**50MG/ML**	**N70691 001**	JUN 19, 1987
AP		**50MG/ML**	**N70849 001**	JUN 19, 1987

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

	METOCLOPRAMIDE HCL			
AP	DUPONT MERCK	**EQ 10MG BASE/2ML**	**N70847 001**	NOV 07, 1988
AP		**EQ 10MG BASE/2ML**	**N71291 001**	MAR 03, 1989
AP	FAULDING	**EQ 10MG BASE/2ML**	**N70847 001**	NOV 07, 1988
AP		**EQ 10MG BASE/2ML**	**N71291 001**	MAR 03, 1989

METOPROLOL TARTRATE

TABLET; ORAL

	METOPROLOL TARTRATE			
AB	LEMMON	**50MG**	**N74141 001**	JAN 31, 1995
AB		**100MG**	**N74141 002**	JAN 31, 1995
AB	PAR PHARM	**50MG**	**N74453 001**	APR 27, 1995
		100MG	N74453 002	APR 27, 1995

METRONIDAZOLE

CAPSULE; ORAL

> ADD >		FLAGYL			
> ADD >	+	SEARLE	375MG	N20334 001	
> ADD >				MAY 03, 1995	

METYRAPONE

TABLET; ORAL

		METOPIRONE			
	+	CIBA	250MG	N12911 001	
	@		250MG	N12911 001	

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

> ADD >		**MEXILETINE HCL**			
> ADD >	**AB**	NOVOPHARM	**150MG**	**N74377 001**	
> ADD >				MAY 16, 1995	
> ADD >	**AB**		**200MG**	**N74377 002**	
> ADD >				MAY 16, 1995	
> ADD >	**AB**		**250MG**	**N74377 003**	
> ADD >				MAY 16, 1995	
		MEXITIL			
> ADD >	**AB**	BOEHRINGER INGELHEIM	**150MG**	**N18873 002**	
> ADD >				DEC 30, 1985	
> ADD >	**AB**		**200MG**	**N18873 003**	
> ADD >				DEC 30, 1985	
> ADD >	**AB**	+	**250MG**	**N18873 004**	
> ADD >				DEC 30, 1985	

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL

		MICONAZOLE NITRATE			
> DLT >	**AB**	ABLE	**200MG**	**N73508 001**	
> DLT >				NOV 19, 1993	
> ADD >	**AB**	NMC	**200MG**	**N73508 001**	
> ADD >				NOV 19, 1993	

MITOMYCIN

INJECTABLE; INJECTION

		MITOMYCIN			
	AP	CETUS BEN VENUE	**5MG/VIAL**	**N64117 001**	
				APR 19, 1995	
			20MG/VIAL	N64117 002	
				APR 19, 1995	

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

	UNIVASC			
	SPKU	7.5MG		N20312 001
				APR 19, 1995
+		15MG		N20312 002
				APR 19, 1995

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

> ADD >	CELLCEPT			
> ADD >	+ SYNTEX	250MG		N50722 001
> ADD >				MAY 03, 1995

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION

REVEX			
OHMEDA	EQ 0.1MG BASE/ML		N20459 001
			APR 17, 1995
+	EQ 1MG BASE/ML		N20459 002
			APR 17, 1995

NAPROXEN

TABLET; ORAL

		NAPROXEN			
> ADD >	**AB**	CHELSEA LABS	**250MG**	**N74457 001**	
> ADD >				MAY 31, 1995	
> ADD >	**AB**		**375MG**	**N74457 002**	
> ADD >				MAY 31, 1995	
> ADD >	**AB**		**500MG**	**N74457 003**	
> ADD >				MAY 31, 1995	

NAPROXEN

TABLET; ORAL
NAPROXEN

AB	DANBURY PHARMA	250MG	N74163 001	FEB 10, 1995
AB		375MG	N74163 002	FEB 10, 1995
AB		500MG	N74163 003	FEB 10, 1995
AB	MOVA	250MG	N74410 001	APR 28, 1995
		375MG	N74410 002	APR 28, 1995
		500MG	N74410 003	APR 28, 1995
AB	ZENITH LABS	250MG	N74111 001	FEB 28, 1995
AB		375MG	N74111 002	FEB 28, 1995
AB		500MG	N74111 003	FEB 28, 1995

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

> ADD > > ADD > > ADD > > ADD >	AB	CHELSEA LABS	EQ 250MG BASE	N74455 001 MAY 31, 1995	> DLT >
	AB		EQ 500MG BASE	N74455 002 MAY 31, 1995	> DLT > > ADD >
	AB	PUREPAC PHARM	EQ 250MG BASE	N74319 001 MAR 20, 1995	> ADD >
	AB		EQ 500MG BASE	N74319 002 MAR 20, 1995	> DLT > > DLT >
	AB	ZENITH LABS	EQ 250MG BASE	N74230 001 MAR 14, 1995	> ADD > > ADD >
	AB		EQ 500MG BASE	N74230 002 MAR 14, 1995	

NEOMYCIN SULFATE

TABLET; ORAL
NEOMYCIN SULFATE

AA	BIOCRAFT	EQ 350MG BASE	N60304 001
		EQ 350MG BASE	N60304 001
AA	LILLY	EQ 350MG BASE	N60385 001

NEOMYCIN SULFATE

TABLET; ORAL
NEOMYCIN SULFATE

@	LILLY	EQ 350MG BASE	N60385 001

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
HABITROL

BC	+	BASEL PHARMS	7MG/24HR	N20076 001 NOV 27, 1991
BC	+		14MG/24HR	N20076 002 NOV 27, 1991
BC	+		21MG/24HR	N20076 003 NOV 27, 1991
BC	+	CIBA	7MG/24HR	N20076 001 NOV 27, 1991
BC	+		14MG/24HR	N20076 002 NOV 27, 1991
BC	+		21MG/24HR	N20076 003 NOV 27, 1991

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL
NICORETTE

+	MERRELL DOW	EQ 2MG BASE	N18612 001 JAN 13, 1984	
+	SMITHKLINE BEECHAM H	EQ 2MG BASE	N18612 001 JAN 13, 1984	

NICORETTE DS

+	MERRELL DOW	EQ 4MG BASE	N20066 001 JUN 08, 1992	
+	SMITHKLINE BEECHAM H	EQ 4MG BASE	N20066 001 JUN 08, 1992	

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL
NISOCOR

+	MILES	10MG	N20356 001 FEB 02, 1995
+		20MG	N20356 002 FEB 02, 1995

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL
NISOCOR

+	MILES	30MG	N20356 003 FEB 02, 1995
+		40MG	N20356 004 FEB 02, 1995

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
NITROFURANTOIN

AB	GENEVA PHARMS	**25MG**	**N74336 001** JAN 25, 1995
AB		**50MG**	**N74336 002** JAN 25, 1995
AB		**100MG**	**N74336 003** JAN 25, 1995

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL
NITRO-DUR

+	KEY PHARMS	0.1MG/HR	N20145 001 APR 04, 1995	
+		0.2MG/HR	N20145 002 APR 04, 1995	> ADD >
+		0.3MG/HR	N20145 003 APR 04, 1995	> DLT >
+		0.4MG/HR	N20145 004 APR 04, 1995	
+		0.6MG/HR	N20145 005 APR 04, 1995	> DLT > > DLT >
+		0.8MG/HR	N20145 006 APR 04, 1995	> ADD > > ADD >

INJECTABLE; INJECTION
NITROSTAT

AP	PARKE DAVIS	**5MG/ML**	**N18588 002** DEC 23, 1983
+		0.8MG/ML	N18588 001
@		0.8MG/ML	N18588 001
@		5MG/ML	N18588 002 DEC 23, 1983

TRIDIL

AP	DUPONT MERCK	**5MG/ML**	**N18537 001**
+		0.5MG/ML	N18537 002 JUN 16, 1983
AP	FAULDING	**5MG/ML**	**N18537 001**
+		0.5MG/ML	N18537 002 JUN 16, 1983

NITROGLYCERIN

INJECTABLE; INJECTION
TRIDIL

+	DUPONT MERCK	0.5MG/ML	N18537 002 JUN 16, 1983
AP	FAULDING	**5MG/ML**	**N18537 001**
+		0.5MG/ML	N18537 002 JUN 16, 1983

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
NORTRIPTYLINE HCL

AB	LEMMON	**EQ 10MG BASE**	**N74132 001** MAR 27, 1995
AB		**EQ 25MG BASE**	**N74132 002** MAR 27, 1995
AB		**EQ 50MG BASE**	**N74132 003** MAR 27, 1995
AB		**EQ 75MG BASE**	**N74132 004** MAR 27, 1995

NYSTATIN

TABLET; ORAL
MYCOSTATIN

AA	+ APOTHECON	**500,000 UNITS**	**N60574 001**
AA	+ SQUIBB	**500,000 UNITS**	**N60574 001**

TABLET; VAGINAL
NYSTATIN

AT	LEMMON	**100,000 UNITS**	**N62502 001** DEC 23, 1983
@		100,000 UNITS	N62502 001 DEC 23, 1983

NYSTATIN; TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL
NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	PHARMAPAIR	**100,000 UNITS/GM;0.1%**	**N62656 001** JUL 30, 1986
@		100,000 UNITS/GM;0.1%	N62656 001 JUL 30, 1986

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION
ZOFRAN IN PLASTIC CONTAINER
+ GLAXO — EQ 0.64MG BASE/ML — N20403 001 JAN 31, 1995

OXYPHENCYCLIMINE HYDROCHLORIDE

> DLT > TABLET; ORAL
> DLT > DARICON
> DLT > + PFIZER — 10MG — N11612 001
> ADD > @ — 10MG — N11612 001

PENICILLAMINE

TABLET; ORAL
DEPEN
+ WALLACE — 250MG — N19854 001
DEPEN 250
+ WALLACE — 250MG — N19854 001

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION
PENICILLIN G POTASSIUM
@ CONSOLIDATED PHARM — 500,000 UNITS/VIAL — N60806 001
@ — 1,000,000 UNITS/VIAL — N60806 002
@ — 5,000,000 UNITS/VIAL — N60806 003
@ — 10,000,000 UNITS/VIAL — N60806 004
@ COPANOS — 500,000 UNITS/VIAL — N60806 001
@ — 1,000,000 UNITS/VIAL — N60806 002
@ — 5,000,000 UNITS/VIAL — N60806 003
@ — 10,000,000 UNITS/VIAL — N60806 004
AP + LILLY — 1,000,000 UNITS/VIAL — N60384 002
AP + — 5,000,000 UNITS/VIAL — N60384 001
AP + — 20,000,000 UNITS/VIAL — N60384 005
AP — 20,000,000 UNITS/VIAL — N60601 001
+ — 200,000 UNITS/VIAL — N60384 004
+ — 500,000 UNITS/VIAL — N60384 003
@ — 200,000 UNITS/VIAL — N60384 004
@ — 500,000 UNITS/VIAL — N60384 003
@ — 1,000,000 UNITS/VIAL — N60384 002
@ — 5,000,000 UNITS/VIAL — N60384 001
@ — 20,000,000 UNITS/VIAL — N60384 005
@ — 20,000,000 UNITS/VIAL — N60601 001

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION
PFIZERPEN
AP PFIZER — 1,000,000 UNITS/VIAL — N60657 001
AP + — 1,000,000 UNITS/VIAL — N60657 001
AP — 5,000,000 UNITS/VIAL — N60657 002
AP + — 5,000,000 UNITS/VIAL — N60657 002
AP — 20,000,000 UNITS/VIAL — N60657 003
AP + — 20,000,000 UNITS/VIAL — N60657 003

TABLET; ORAL
PENICILLIN G POTASSIUM
AB DISTA — 250,000 UNITS — N60403 001
@ LILLY — 250,000 UNITS — N60403 001

PENICILLIN G PROCAINE

INJECTABLE; INJECTION
PENICILLIN G PROCAINE
@ CONSOLIDATED PHARM — 300,000 UNITS/ML — N60800 001
@ — 600,000 UNITS/1.2ML — N60800 002
@ COPANOS — 300,000 UNITS/ML — N60800 001
@ — 600,000 UNITS/1.2ML — N60800 002

PENICILLIN V POTASSIUM

POWDER FOR RECONSTITUTION; ORAL
PENICILLIN V POTASSIUM
AA CONSOLIDATED PHARM — EQ 125MG BASE/5ML — N61529 001
AA — EQ 250MG BASE/5ML — N61529 002
AA COPANOS — EQ 125MG BASE/5ML — N61529 001
AA — EQ 250MG BASE/5ML — N61529 002

TABLET; ORAL
PENICILLIN V POTASSIUM
AB CONSOLIDATED PHARM — EQ 250MG BASE — N61528 001
AB — EQ 500MG BASE — N61528 002
AB COPANOS — EQ 250MG BASE — N61528 001
AB — EQ 500MG BASE — N61528 002

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION
PENTACARINAT
> ADD > AP ARMOUR — 300MG/VIAL — N73447 001 APR 28, 1994
> ADD >

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION
PENTACARINAT
> DLT > AP RHONE POULENC RORER 300MG/VIAL N73447 001
> DLT APR 28, 1994

PERINDOPRIL ERBUMINE

TABLET; ORAL
ACEON
AMARIC 2MG N20184 001
DEC 30, 1993
4MG N20184 002
DEC 30, 1993
+ 8MG N20184 003
DEC 30, 1993
JOHNSON RW 2MG N20184 001
DEC 30, 1993
4MG N20184 002
DEC 30, 1993
+ 8MG N20184 003
DEC 30, 1993

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
MELFIAT-105
> ADD > @ NUMARK 105MG N87487 001
> ADD > OCT 13, 1982
> DLT > @ SOLVAY 105MG N87487 001
> DLT > OCT 13, 1982
SPRX-105
> ADD > @ NUMARK 105MG N88024 001
> ADD > DEC 22, 1982
> DLT > @ SOLVAY 105MG N88024 001
> DLT > DEC 22, 1982

TABLET; ORAL
MELFIAT
> ADD > @ NUMARK 35MG N83790 002
> DLT > @ SOLVAY 35MG N83790 002
PHENDIMETRAZINE TARTRATE
> ADD > @ NUMARK 35MG N83790 001
> DLT > @ SOLVAY 35MG N83790 001

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HCL
> DLT > AA LEMMON 30MG N87777 001
> DLT > NOV 01, 1985
> ADD > @ 30MG N87777 001
> ADD > NOV 01, 1985

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL
IONAMIN
FISONS EQ 15MG BASE N11613 004
+ EQ 30MG BASE N11613 002
IONAMIN-15
FISONS EQ 15MG BASE N11613 004
IONAMIN-30
+ FISONS EQ 30MG BASE N11613 002

PINDOLOL

TABLET; ORAL
PINDOLOL
AB ROYCE LABS 5MG N74437 001
FEB 27, 1995
AB 10MG N74437 002
FEB 27, 1995

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

POWDER FOR RECONSTITUTION; ORAL
NULYTELY-FLAVORED
BRAINTREE 420GM/BOT;1.48GM/BOT;5.72GM/BOT; 11.2GM/BOT N19797 002
NOV 18, 1994

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL

	GOLYTELY				
AA	BRAINTREE	227.1GM/PACKET;2.82GM/PACKET; 6.36GM/PACKET;5.53GM/PACKET; 21.5GM/PACKET	N19011 002 JUN 02, 1992	> ADD >	
				> ADD >	
				> DLT >	
				> DLT >	
				> DLT >	

POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

	MINIZIDE				
	PFIZER	0.5MG;1MG	N17986 001	> ADD >	
		0.5MG;2MG	N17986 002	> DLT >	
		0.5MG;5MG	N17986 003		
*		0.5MG;EQ 1MG BASE	N17986 001		
		0.5MG;EQ 2MG BASE	N17986 002		
+		0.5MG;EQ 5MG BASE	N17986 003		

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	KAON CL				
	SAVAGE LABS	6.7MEQ	N17046 001		
@		6.7MEQ	N17046 001		
	KAON CL-10				
BC	SAVAGE LABS	10MEQ	N17046 002		
@		10MEQ	N17046 002		

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

	HYDELTRASOL				
AP	* MERCK SHARP DOHME	EQ 20MG PHOSPHATE/ML	N11583 002		
+		EQ 20MG PHOSPHATE/ML	N11583 002		
	PREDNISOLONE SODIUM PHOSPHATE				
AP	STERIS	EQ 20MG PHOSPHATE/ML	N80517 001		
@		EQ 20MG PHOSPHATE/ML	N80517 001		

PROCAINAMIDE HYDROCHLORIDE

TABLET; ORAL

	PRONESTYL				
> ADD >	APOTHECON	250MG	N17371 001		
	APOTHECON	375MG	N17371 002	> ADD >	
		500MG	N17371 003	> ADD >	
+	SQUIBB	250MG	N17371 001	> DLT >	
		375MG	N17371 002	> DLT >	
+		500MG	N17371 003	> DLT >	

TABLET, EXTENDED RELEASE; ORAL

	PROCAN SR				
AB	PARKE DAVIS	250MG	N86468 001		
@		250MG	N86468 001		
	PRONESTYL-SR				
BC	APOTHECON	500MG	N87361 001		
BC	BRISTOL MYERS SQUIBB	500MG	N87361 001		

PROPANTHELINE BROMIDE

TABLET; ORAL

	PROPANTHELINE BROMIDE				
AA	DANBURY PHARMA	15MG	N83029 002		
@		15MG	N83029 002		
AA	GLOBAL PHARMS	15MG	N84541 002		
@		15MG	N84541 002		
AA	TABLICAPS	15MG	N84428 001		
@		15MG	N84428 001		

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	OPHTHAINE				
AT	+ APOTHECON	0.5%	N08883 001	> ADD >	
AT	+ SQUIBB	0.5%	N08883 001	> DLT >	

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

	PROPRANOLOL HCL				
AB	PARKE DAVIS	20MG	N70439 001 SEP 15, 1986	> DLT >	
				> DLT >	
AB		40MG	N70440 001 SEP 15, 1986	> DLT >	
				> DLT >	
AB		60MG	N70441 001 SEP 24, 1986	> DLT >	
				> DLT >	

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

> DLT >	AB	PARKE DAVIS	80MG	N70442 001	
> DLT				SEP 15, 1986	
> DLT >	AB	WARNER CHILCOTT	10MG	N70438 001	
> DLT >				SEP 15, 1986	
> ADD >		@	10MG	N70438 001	
> ADD >				SEP 15, 1986	
> ADD >		@	20MG	N70439 001	
> ADD >				SEP 15, 1986	
> ADD >		@	40MG	N70440 001	
> ADD >				SEP 15, 1986	
> ADD >		@	60MG	N70441 001	
> ADD >				SEP 24, 1986	
> ADD >		@	80MG	N70442 001	
> ADD >				SEP 15, 1986	

PROPYLTHIOURACIL

TABLET; ORAL
PROPYLTHIOURACIL

BD	LILLY	50MG	N06213 001	
	@	50MG	N06213 001	

QUINESTROL

> DLT >		TABLET; ORAL			
> DLT >		ESTROVIS			
> DLT >		+ PARKE DAVIS	0.1MG	N16768 002	
> ADD >		@	0.1MG	N16768 002	

SECOBARBITAL SODIUM

CAPSULE; ORAL
SECOBARBITAL SODIUM

AA	ZENITH LABS	100MG	N85869 001	
	@	100MG	N85869 001	

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	BAXTER	9MG/ML	N16677 004	
			OCT 30, 1985	

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	+	BAXTER	9MG/ML	N16677 004	
				OCT 30, 1985	

SOLUTION; IRRIGATION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

> DLT >	AT	BAXTER	450MG/100ML	N18497 001	
> DLT >				FEB 19, 1982	
> ADD >		@	450MG/100ML	N18497 001	
> ADD >				FEB 19, 1982	

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION
BIO-TROPIN

> ADD >		+ BIO TECH GEN	4.8MG/VIAL	N19774 001
> ADD >				MAY 25, 1995
> ADD >		NORDITROPIN		
> ADD >		+ NOVO NORDISK	4MG/VIAL	N19721 001
> ADD >				MAY 08, 1995
> ADD >		+	8MG/VIAL	N19721 002
> ADD >				MAY 08, 1995

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION
STREPTOMYCIN SULFATE

AP	LILLY	EQ 1GM BASE/VIAL	N60107 001	
AP		EQ 5GM BASE/VIAL	N60107 002	
		EQ 1GM BASE/2ML	N60404 001	
	@	EQ 1GM BASE/2ML	N60404 001	
	@	EQ 1GM BASE/VIAL	N60107 001	
	@	EQ 5GM BASE/VIAL	N60107 002	
AP	+ PFIZER	EQ 1GM BASE/VIAL	N60076 001	
AP	+	EQ 5GM BASE/VIAL	N60076 002	
	+	EQ 1GM BASE/VIAL	N60076 001	
	+	EQ 5GM BASE/VIAL	N60076 002	

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION
SUCOSTRIN

AP	APOTHECON	20MG/ML	N08847 001	

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION
SUCOSTRIN
@ APOTHECON 100MG/ML N08847 003
AP SQUIBB 20MG/ML N08847 001
@ 100MG/ML N08847 003

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL
TRIMETH/SULFA
> DLT > AB BARRE 200MG/5ML;40MG/5ML N72289 001
> DLT > MAY 23, 1988
> ADD > @ 200MG/5ML;40MG/5ML N72289 001
> ADD > MAY 23, 1988

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL
TECHNELITE
DUPONT 0.0083-2.7 CI/GENERATOR N17771 001
TECHNETIUM TC 99M GENERATOR
DUPONT 0.0083-2.7 CI/GENERATOR N17771 001

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
TETRACYCLINE HCL
AB PVT FORM 250MG N62686 001
JUL 24, 1986
AB 500MG N62686 002
JUL 24, 1986
@ 250MG N62686 001
JUL 24, 1986
@ 500MG N62686 002
JUL 24, 1986

FIBER, EXTENDED RELEASE; PERIODONTAL
ACTISITE
+ ON SITE 12.7MG/FIBER N50653 001
MAR 25, 1994
+ ON SITE ALZA 12.7MG/FIBER N50653 001
MAR 25, 1994

> ADD > OINTMENT; OPHTHALMIC
> ADD > ACHROMYCIN
> ADD > + LEDERLE 10MG/GM N50266 001

TETRACYCLINE HYDROCHLORIDE

> DLT > OINTMENT; OPHTHALMIC, OTIC
> DLT > ACHROMYCIN
> DLT > + LEDERLE 10MG/GM N50266 001

> ADD > SUSPENSION; ORAL
> ADD > ACHROMYCIN V
> ADD > AB + LEDERLE 125MG/5ML N50263 002
> ADD > SUMYCIN
> ADD > AB APOTHECON 125MG/5ML N60400 001
> ADD > TETRACYCLINE HCL
> ADD > AB BARRE 125MG/5ML N60633 001
> ADD > AB MK LABS 125MG/5ML N60174 001
> ADD > AB PUREPAC PHARM 125MG/5ML N60291 001
> ADD > TETRACYN
> ADD > AB PFIPHARMECS 125MG/5ML N60095 001
> ADD > TETRAMED
> ADD > AB ZENITH LABS 125MG/5ML N61468 001

> DLT > SYRUP; ORAL
> DLT > ACHROMYCIN V
> DLT > AB + LEDERLE 125MG/5ML N50263 002
> DLT > SUMYCIN
> DLT > AB SQUIBB 125MG/5ML N60400 001
> DLT > TETRACYCLINE HCL
> DLT > AB BARRE 125MG/5ML N60633 001
> DLT > AB MK LABS 125MG/5ML N60174 001
> DLT > AB PUREPAC PHARM 125MG/5ML N60291 001
> DLT > TETRACYN
> DLT > AB PFIPHARMECS 125MG/5ML N60095 001
> DLT > TETRAMED
> DLT > AB ZENITH LABS 125MG/5ML N61468 001

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL
THEOPHYLLINE
BC FAULDING 100MG N89976 001
JAN 04, 1995
BC 200MG N89977 001
JAN 04, 1995
BC 300MG N89932 001
JAN 04, 1995

TABLET, EXTENDED RELEASE; ORAL
LABID
BC + PROCTER AND GAMBLE 250MG N87225 001

THEOPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

		LABID		
		@ PROCTER AND GAMBLE	250MG	N87225 001
		THEOLAIR-SR		
BC		3M	250MG	N86363 002 JUL 16, 1987
			250MG	N86363 002 JUL 16, 1987
		THEOPHYLLINE		
AB		**INWOOD LABS**	**450MG**	**N40034 001** APR 28, 1995
		UNI-DUR		
BC	+	KEY PHARMS	400MG	N89822 001 JAN 04, 1995
	+		600MG	N89823 001 JAN 04, 1995
		UNIPHYL		
BC		PURDUE FREDERICK	400MG	N87571 001 SEP 01, 1982

THIOTEPA

INJECTABLE; INJECTION

		THIOPLEX		
		IMMUNEX	15MG/VIAL	N20058 001 DEC 22, 1994
AP		**LEDERLE**	**15MG/VIAL**	**N20058 001** DEC 22, 1994
		THIOTEPA		
AP	+	**IMMUNEX**	**15MG/VIAL**	**N11683 001**
	+		15MG/VIAL	N11683 001

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

		BETIMOL		
	+	LEIRAS	EQ 0.25% BASE	N20439 001 MAR 31, 1995
	+		EQ 0.5% BASE	N20439 002 MAR 31, 1995

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

		TIMOLOL MALEATE		
AT		**ALCON**	**EQ 0.25% BASE**	**N74261 001** APR 28, 1995
AT			**EQ 0.5% BASE**	**N74262 001** APR 28, 1995
		TIMOPTIC		
AT	+	**MERCK**	**EQ 0.25% BASE**	**N18086 001**
AT	+		**EQ 0.5% BASE**	**N18086 002**

TIOCONAZOLE

OINTMENT; VAGINAL

		VAGISTAT-1		
	+	BRISTOL MYERS	6.5%	N19355 001 DEC 30, 1986
	+	BRISTOL MYERS SQUIBB	6.5%	N19355 001 DEC 30, 1986

TOCAINIDE HYDROCHLORIDE

TABLET; ORAL

		TONOCARD		
		ASTRA MERCK	400MG	N18257 001 NOV 09, 1984
	+		600MG	N18257 002 NOV 09, 1984
		MERCK SHARP DOHME	400MG	N18257 001 NOV 09, 1984
	+		600MG	N18257 002 NOV 09, 1984

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

		ULTRAM		
	+	JOHNSON RW	50MG	N20281 002 MAR 03, 1995
	@		100MG	N20281 001 MAR 03, 1995

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
KENALOG-H
> ADD > AT APOTHECON 0.1% N86240 001
> DLT > AT WESTWOOD SQUIBB 0.1% N86240 001

INJECTABLE; INJECTION
KENALOG-10
> ADD > + APOTHECON 10MG/ML N12041 001
> DLT > + WESTWOOD SQUIBB 10MG/ML N12041 001
KENALOG-40
> ADD > BP APOTHECON 40MG/ML N14901 001
> DLT > BP WESTWOOD SQUIBB 40MG/ML N14901 001

LOTION; TOPICAL
KENALOG
> ADD > AT APOTHECON 0.025% N84343 001
> ADD > AT + 0.1% N84343 002
> ADD > @ 0.025% N11602 003
> ADD > @ 0.1% N11602 001
> DLT > AT WESTWOOD SQUIBB 0.025% N84343 001
> DLT > AT + 0.1% N84343 002
> DLT > @ 0.025% N11602 003
> DLT > @ 0.1% N11602 001

OINTMENT; TOPICAL
TRIAMCINOLONE ACETONIDE IN ABSORBASE
+ CAROLINA MEDCL 0.05% N89595 001
MAR 23, 1995

PASTE; DENTAL
KENALOG IN ORABASE
> ADD > AT + APOTHECON 0.1% N12097 001
> DLT > AT + SQUIBB 0.1% N12097 001

TRICHLORMETHIAZIDE

TABLET; ORAL
NAQUA
> DLT > BP SCHERING 2MG N12265 001
> ADD > @ 2MG N12265 001

TRILOSTANE

CAPSULE; ORAL
MODRASTANE
SANOFI WINTHROP 30MG N18719 002
DEC 31, 1984
+ 60MG N18719 001
DEC 31, 1984
@ 30MG N18719 002
DEC 31, 1984
@ 60MG N18719 001
DEC 31, 1984

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION
TUBOCURARINE CHLORIDE
> ADD > AP + APOTHECON 3MG/ML N05657 001
> DLT > AP + SQUIBB 3MG/ML N05657 001

VALPROIC ACID

SYRUP; ORAL
VALPROIC ACID
AA HIGH TECH PHARMA 250MG/5ML N74060 001
JAN 13, 1995

VANCOMYCIN HYDROCHLORIDE

POWDER FOR RECONSTITUTION; ORAL
VANCOCIN HCL
AB + LILLY EQ 500MG BASE/6ML N61667 001
+ EQ 500MG BASE/6ML N61667 001
VANCOLED
AB LEDERLE EQ 500MG BASE/6ML N63321 003
OCT 15, 1993
@ EQ 500MG BASE/6ML N63321 003
OCT 15, 1993

VITAMIN A

CAPSULE; ORAL
VITAMIN A
AA BANNER PHARMACAPS 50,000 USP UNITS N83973 001
@ 50,000 USP UNITS N83973 001

VITAMIN A PALMITATE

CAPSULE; ORAL

	VITAMIN A		
AA	BANNER PHARMACAPS	**EQ 50,000 UNITS BASE**	**N80702 001**
	@	EQ 50,000 UNITS BASE	N80702 001
	VITAMIN A PALMITATE		
AA	BANNER PHARMACAPS	**EQ 50,000 UNITS BASE**	**N83948 001**
	@	EQ 50,000 UNITS BASE	N83948 001

WARFARIN SODIUM

INJECTABLE; INJECTION

	COUMADIN		
+	DUPONT MERCK	5MG/VIAL	N09218 024 FEB 07, 1995

ACETAMINOPHEN

SUPPOSITORY; RECTAL
ACETAMINOPHEN
ABLE 120MG N73106 001 FEB 27, 1995
325MG N73107 001 FEB 27, 1995
650MG N73108 001 FEB 27, 1995

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

> ADD > SOLUTION/DROPS; OPHTHALMIC
> ADD > VASOCON-A
> ADD > + CIBA 0.5%;0.05% N18746 002 JUL 11, 1994
> ADD >

FAMOTIDINE

TABLET; ORAL
PEPCID AC
+ MERCK 10MG N20325 001 APR 28, 1995

IBUPROFEN

CAPSULE; ORAL
MIDOL
+ WINTHROP 200MG N70626 001 SEP 02, 1987
200MG N71002 001 SEP 02, 1987
@ 200MG N70626 001 SEP 02, 1987
@ 200MG N71002 001 SEP 02, 1987

> DLT > PROVEL
> DLT > + SANDOZ 200MG N20402 001 APR 20, 1995

TABLET; ORAL
MIDOL
WINTHROP 200MG N70591 001 SEP 02, 1987

IBUPROFEN

TABLET; ORAL
MIDOL
WINTHROP 200MG N71001 001 SEP 02, 1987
@ 200MG N70591 001 SEP 02, 1987
@ 200MG N71001 001 SEP 02, 1987

INSULIN PORK

INJECTABLE; INJECTION
INSULIN
+ NOVO NORDISK 100 UNITS/ML N17926 003
REGULAR INSULIN
+ NOVO NORDISK 100 UNITS/ML N17926 003

INSULIN PURIFIED PORK

INJECTABLE; INJECTION
VELOSULIN
NOVO NORDISK 100 UNITS/ML N18193 001
@ 100 UNITS/ML N18193 001

INSULIN PURIFIED PORK; INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION
INSULIN NORDISK MIXTARD (PORK)
+ NOVO NORDISK 30 UNITS/ML;70 UNITS/ML N18195 001
@ 30 UNITS/ML;70 UNITS/ML N18195 001

INSULIN SEMISYNTHETIC PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

> DLT > INJECTABLE; INJECTION
> DLT > MIXTARD HUMAN 70/30
> DLT > + NOVO NORDISK 30 UNITS/ML;70 UNITS/ML N19585 001 MAR 11, 1988
> DLT > @ 30 UNITS/ML;70 UNITS/ML N19585 001 MAR 11, 1988
> ADD > NOVOLIN 70/30
> ADD > + NOVO NORDISK 30 UNITS/ML;70 UNITS/ML N19441 001 JUL 11, 1986

INSULIN SEMISYNTHETIC PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION
NOVOLIN 70/30

@	NOVO NORDISK	30 UNITS/ML;70 UNITS/ML	N19441 001 JUL 11, 1986

INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION
INSULIN INSULATARD NPH NORDISK

+	NOVO NORDISK	100 UNITS/ML	N18194 001
@		100 UNITS/ML	N18194 001

INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF

INJECTABLE; INJECTION
PROTAMINE ZINC AND ILETIN II

+	LILLY	100 UNITS/ML	N18476 001
@		100 UNITS/ML	N18476 001

PROTAMINE ZINC INSULIN

	SQUIBB	100 UNITS/ML	N17928 003
+		100 UNITS/ML	N17928 003

MICONAZOLE NITRATE

CREAM; VAGINAL
MICONAZOLE NITRATE

LEMMON	2%	N74136 001 JAN 04, 1995

NAPROXEN SODIUM

TABLET; ORAL
ALEVE

HAMILTON PHARMS	EQ 200MG BASE	N20204 002 JAN 11, 1994
+	EQ 200MG BASE	N20204 002 JAN 11, 1994

NONOXYNOL-9

AEROSOL; VAGINAL
DELFEN

@	ORTHO	12.5%	N14349 002

POTASSIUM IODIDE

SOLUTION; ORAL
POTASSIUM IODIDE

+	ROXANE	1GM/ML	N18551 001 FEB 19, 1982
@		1GM/ML	N18551 001 FEB 19, 1982

PYRITHIONE ZINC

LOTION; TOPICAL
HEAD & SHOULDERS CONDITIONER

+	PROCTER AND GAMBLE	0.3%	N19412 002 MAR 10, 1986
@		0.3%	N19412 002 MAR 10, 1986

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
6% HETASTARCH IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
ABBOTT 6GM/100ML;0.9GM/100ML N74193
JAN 30, 1995

LIST OF ORPHAN PRODUCT DESIGNATIONS & APPROVALS
[January - May, 1995]

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
ADENO-AS'TED VIRAL-BASED VECTOR CYSTIC FIBROSIS GENE THERAPY TN=	TREATMENT OF CYSTIC FIBROSIS.	TARGETED GENETICS CORPORATION 1100 OLIVE WAY, SUITE 100 SEATTLE WA 98101 DD 02/15/95 MA / /
AMINOCAPROIC ACID TN=	FOR THE TOPICAL TREATMENT OF TRAUMATIC HYPHEMA OF THE EYE.	ORPHAN MEDICAL 13911 RIDGEDALE DRIVE MINNETONKA MN 55305 DD 01/06/95 MA / /
APL 400-020 TN=	TREATMENT OF CUTANEOUS T CELL LYMPHOMA.	APOLLON, INC. ONE GREAT VALLEY PARKWAY MALVERN PA 19355 DD 03/08/95 MA / /
CHONDROITINASE TN=	TREATMENT OF PATIENTS UNDERGOING VITRECTOMY.	STORZ OPHTHALMICS AMERICAN CYANAMID COMPANY PEARL RIVER NY 10965 DD 02/09/95 MA / /
CLOTRIMIDAZOLE TN=	TREATMENT OF SICKLE CELL DISEASE.	BRUGNARA, CARLO M.D. THE CHILDREN'S HOSPITAL BOSTON MA 02115 DD 04/24/95 MA / /
CYSTIC FIBROSIS TR GENE THERAPY (RECOMBINANT ADENOVIRUS) TN= ADgvCFTR.10	TREATMENT OF CYSTIC FIBROSIS.	GENVAC, INCORPORATED 12111 PARKLAWN DRIVE ROCKVILLE MD 20852 DD 03/09/95 MA / /
GLUTAMINE TN=	FOR USE WITH HUMAN GROWTH HORMONE IN THE TREATMENT OF SHORT BOWEL SYNDROME (NUTRIENT MALABSORPTION FROM THE GASTROINTESTINAL TRACT RESULTING FROM AN INADEQUATE ABSORPTIVE SURFACE).	RESEARCH TRIANGLE PHARMACEUTICALS 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 DD 03/06/95 MA / /
GLYCERYL TRIOLEATE AND GLYCERYL TRIERUCATE TN=	TREATMENT OF ADRENOLEUKODYSTROPHY.	MOSER, HUGO W. M.D. JOHNS HOPKINS UNIVERSITY BALTIMORE MD 21205 DD 02/14/95 MA / /
HEPATITIS B IMMUNE GLOBULIN, INTRAVENOUS TN= H-BIGIV	PROPHYLAXIS AGAINST HEPATITIS B VIRUS REINFECTION IN LIVER TRANSPLANT PATIENTS.	NORTH AMERICAN BIOLOGICS, INC. 16500 N.W. 15th AVENUE MIAMI FL 33169 DD 03/08/95 MA / /
HUMAN GROWTH HORMONE TN=	FOR USE WITH GLUTAMINE IN THE TREATMENT OF SHORT BOWEL SYNDROME (NUTRIENT MALABSORPTION FROM THE GASTROINTESTINAL TRACT RESULTING FROM AN INADEQUATE ABSORPTIVE SURFACE).	RESEARCH TRIANGLE PHARMACEUTICALS 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 DD 03/06/95 MA / /
HUMAN IMMUNODEFICIENCY VIRUS IMMUNE GLOBULIN TN= HIVIG	TREATMENT OF HIV-INFECTED PEDIATRIC PATIENTS.	NORTH AMERICAN BIOLOGICALS, INC. 16500 N.W. 15TH AVENUE MIAMI FL 33169 DD 01/04/95 MA / /
NTBC TN=	TREATMENT OF TYROSINEMIA TYPE 1.	SWEDISH ORPHAN AB ORPHAN PHARMACEUTICAL, USA, INC. NASHVILLE TN 37217 DD 05/16/95 MA / /

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
PHENYLALANINE AMMONIA-LYASE TN= PHENYLASE	TREATMENT OF HYPERPHENYLALANINEMIA.	IBEX TECHNOLOGIES, INC. 5485 PARE MONTREAL, QUEBEC DD 03/08/95 MA / /
PURIFIED TYPE II COLLAGEN TN= COLLORAL	TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS.	AUTOIMMUNE, INCORPORATED 128 SPRING STREET LEXINGTON MA 02173 DD 02/09/95 MA / /
RECOMBINANT HUMAN GELSOLIN TN=	TREATMENT OF ACUTE AND CHRONIC RESPIRATORY SYMPTOMS OF BRONCHIECTASIS.	BIOGEN, INCORPORATED 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142 DD 03/06/95 MA / /
SARGRAMOSTIM TN= LEUKINE	TO REDUCE NEUTROPENIA AND LEUKOPENIA AND DECREASE THE INCIDENCE OF DEATH DUE TO INFECTION IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA.	IMMUNEX CORPORATION 51 UNIVERSITY STREET SEATTLE WA 98101 DD 03/06/95 MA / /
SU-101 TN=	TREATMENT OF MALIGNANT GLIOMA.	SUGEN, INC. 515 GALVESTON DRIVE REDWOOD CITY CA 94063-4720 DD 05/25/95 MA / /
THALIDOMIDE TN=	TREATMENT OF SEVERE RECURRENT APHTHOUS STOMATITIS IN SEVERELY, TERMINALLY IMMUNOCOMPROMISED PATIENTS.	CELGENE CORPORATION P.O. BOX 4914 WARREN NJ 07059 DD 05/01/95 MA / /
THALIDOMIDE TN=	TREATMENT AND PREVENTION OF RECURRENT APHTHOUS ULCERS IN SEVERELY, TERMINALLY IMMUNOCOMPROMISED PATIENTS.	ANDRULIS RESEARCH CORPORATION 11800 BALTIMORE AVENUE, SUITE 113 BELTSVILLE MD 20705 DD 05/15/95 MA / /
TYLOXAPOL TN=	TREATMENT OF CYSTIC FIBROSIS.	KENNEDY & HOIDAL, MDs 50 NORTH MEDICAL DRIVE, U OF UTAH SALT LAKE CITY UT 84132 DD 03/08/95 MA / /

Approved Orphan Products

Rho (D) IMMUNE GLOBULIN INTRAVENOUS (HUMAN) TN= WinRho SD	TREATMENT OF IMMUNE THROMBOCYTOPENIC PURPURA.	RH PHARMACEUTICALS, INC. 104 CHANCELLOR MATHESON ROAD WINNIPEG, MANITOBA DD 11/09/93 MA 03/24/95

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO MAY 1995 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR *IN VIVO* BIOEQUIVALENCE STUDIES AND *IN VITRO* DISSOLUTION TESTING. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE (HFD-650, MPN-2 ROOM 279) 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 15TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

NO MAY 1995 GUIDANCES

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 1-23, PARK BUILDING, 5600 FISHERS LANE, ROCKVILLE, MD 20857.					
REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 15TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.					
ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE TABLET; ORAL	150MG 180MG 15MG	94 P-0212/ CP1	MIKART	NEW DOSAGE FORM	APPROVED JAN 19, 1995
ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE TABLET; ORAL	150MG 180MG 30MG	94 P-0211/ CP1	MIKART	NEW DOSAGE FORM	APPROVED JAN 19, 1995
ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE TABLET; ORAL	150MG 180MG 60MG	94 P-0210/ CP1	MIKART	NEW DOSAGE FORM	APPROVED JAN 19, 1995
ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE TABLET; ORAL	712.8MG 60MG 32MG	93 P-0484/ CP1	MIKART	NEW DOSAGE FORM NEW STRENGTH	APPROVED JAN 19, 1995
ACETAMINOPHEN; CODEINE PHOSPHATE TABLET, CHEWABLE; ORAL	120MG 12MG	94 P-0182/ CP1	WE PHARMS	NEW DOSAGE FORM	APPROVED JAN 19, 1995
ALBUTEROL SULFATE TABLET, CHEWABLE; ORAL	EQ 2MG BASE EQ 4MG BASE	92 P-0335/ CP1	WE PHARMS	NEW DOSAGE FORM	APPROVED JAN 19, 1995
ATRACURIUM BESLYLATE INJECTABLE; INJECTION	25MG/ML	94 P-0314/ CP1	ABBOTT	NEW STRENGTH	APPROVED MAY 02, 1995
LEUCOVORIN CALCIUM INJECTABLE; INJECTION	EQ 10MG BASE/ML (100MG/VIAL)	93 P-0427/ CP3	ABBOTT	NEW DOSAGE FORM	APPROVED JAN 19, 1995
LEUCOVORIN CALCIUM INJECTABLE; INJECTION	EQ 10MG BASE/ML (250MG/VIAL)	93 P-0427/ CP2	ABBOTT	NEW DOSAGE FORM NEW STRENGTH	APPROVED JAN 19, 1995
SULFAMETHOXAZOLE; TRIMETHOPRIM TABLET, CHEWABLE; ORAL	200MG 40MG	94 P-0186/ CP1	DURA PHARMS	NEW DOSAGE FORM	APPROVED JAN 19, 1995
THIORIDAZINE HYDROCHLORIDE SOLUTION; ORAL	25MG/5ML	92 P-0283/ CP1	UDL LABS	NEW STRENGTH	APPROVED JAN 19, 1995

ANDA SUITABILITY PETITIONS

PETITIONS DENIED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
NICOTINE POLACRILEX LOLLIPOP; ORAL	2MG	93 P-0414/ CP1	SAVAGE	NEW DOSAGE FORM	DENIED MAY 02, 1995

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 15TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES

NEW DOSING SCHEDULE

D-26	ONCE WEEKLY APPLICATION
D-27	BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
D-28	REVISED BASIS FOR CALCULATING THE RECOMMENDED STARTING DOSE IN ACCORDANCE WITH THE 1993 NATIONAL CHOLESTEROL EDUCATION PROGRAM GUIDELINES - DOSING RANGE EXPANDED TO 10-80MG/DAY

REFERENCES

NEW INDICATION

I-117	TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE
I-118	PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLSIM, FOLLOWING KNEE REPLACEMENT SURGERY
I-119	TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY
I-120	MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS
I-121	EXPANDED PATIENT POPULATION - USE IN ICU PATIENTS
I-122	PSORIASIS OF THE SCALP
I-123	RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER
I-124	LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE
I-125	EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES
I-126	ADJUNCT TO THALLIUM-201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY

REFERENCES

PATENT USE CODE

U-102	METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN
U-103	TREATMENT OF OCULAR HYPERTENSION
U-104	TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE
U-105	EMESIS
U-106	TREATMENT OF EPILEPSY
U-107	TREATMENT OF HYPERTENSION AND ANGINA PECTORIS
U-108	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-109	USE AS AN ADJUNCT TO DIET IN THE TREATMENT OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SATURATED FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	19872 001	ACETAMINOPHEN; TYLENOL	5004613	APR 11, 2006			
>ADD>			4968509	NOV 06, 2007			
>ADD>			4820522	APR 11, 2006		NDF	JUN 08, 1997
>ADD>	20059 001	ADENOSINE; ADENOSCAN				I-126	MAY 18, 1998
	20364 002	AMLODIPINE BESYLATE; LOTREL	4879303	NOV 07, 2006		NC	MAR 03, 1998
			4572909	AUG 01, 2006		NCE	JUN 25, 1996
			4410520	OCT 18, 2002		NCE	JUL 31, 1997
	20364 003	AMLODIPINE BESYLATE; LOTREL	4879303	NOV 07, 2006		NC	MAR 03, 1998
			4572909	AUG 01, 2006		NCE	JUN 25, 1996
			4410520	OCT 18, 2002		NCE	JUL 31, 1997
	20364 004	AMLODIPINE BESYLATE; LOTREL	4879303	NOV 07, 2006		NC	MAR 03, 1998
			4572909	AUG 01, 2006		NCE	JUN 25, 1996
			4410520	OCT 18, 2002		NCE	JUL 31, 1997
	20500 001	ATOVAQUONE; MEPRON	5053432	OCT 01, 2008		NCE	NOV 25, 1997
			4981874	AUG 15, 2009	U-69	NDF	FEB 08, 1998
	20222 001	COLESTIPOL HYDROCHLORIDE; COLESTID				NDF	JUL 19, 1997
	20287 001	DALTEPARIN SODIUM; FRAGMIN	4303651	JAN 04, 2000		NCE	DEC 22, 1999
>ADD>	20212 001	DEXZAZOXANE; ZINECARD				NCE	MAY 26, 2000
>ADD>	20212 002	DEXZAZOXANE; ZINECARD				NCE	MAY 26, 2000
	20092 001	DILTIAZEM HYDROCHLORIDE; DILACOR XR				I-120	OCT 15, 1995
	20092 002	DILTIAZEM HYDROCHLORIDE; DILACOR XR				I-120	OCT 15, 1995
	20092 003	DILTIAZEM HYDROCHLORIDE; DILACOR XR				I-120	OCT 15, 1995
	20411 001	DINOPROSTONE; CERVIDIL				NDF	MAR 30, 1998
	20408 001	DORZOLAMIDE HYDROCHLORIDE; TRUSOPT	4797413	JUN 30, 2004	U-103	NCE	DEC 09, 1999
			4619939	OCT 28, 2003	U-104		
	19946 001	DOXACURIUM CHLORIDE; NUROMAX				I-121	DEC 08, 1997
	19668 001	DOXAZOSIN MESYLATE; CARDURA				I-96	FEB 06, 1998
	19668 002	DOXAZOSIN MESYLATE; CARDURA				I-96	FEB 06, 1998
	19668 003	DOXAZOSIN MESYLATE; CARDURA				I-96	FEB 06, 1998
	19668 004	DOXAZOSIN MESYLATE; CARDURA				I-96	FEB 06, 1998
	20164 001	ENOXAPARIN SODIUM; LOVENOX				I-118	MAR 09, 1998

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20323 001	ESTRADIOL; VIVELLE	5300291	APR 05, 2011		NS	OCT 28, 1997
			4994278	FEB 19, 2008			
			4994267	FEB 19, 2008			
			4814168	MAR 21, 2006			
	20323 002	ESTRADIOL; VIVELLE	5300291	APR 05, 2011			
			4994278	FEB 19, 2008			
			4994267	FEB 19, 2008			
			4814168	MAR 21, 2006			
	20323 003	ESTRADIOL; VIVELLE	5300291	APR 05, 2011		NS	OCT 28, 1997
			4994278	FEB 19, 2008			
			4994267	FEB 19, 2008			
			4814168	MAR 21, 2006			
	20323 004	ESTRADIOL; VIVELLE	5300291	APR 05, 2011			
			4994278	FEB 19, 2008			
			4994267	FEB 19, 2008			
			4814168	MAR 21, 2006			
	20375 001	ESTRADIOL; CLIMARA	5223261	JUN 29, 2010		D-26	DEC 22, 1997
	20375 002	ESTRADIOL; CLIMARA	5223261	JUN 29, 2010		D-26	DEC 22, 1997
	20303 001	ESTROGENS, CONJUGATED; PREMPRO (PREMARIN;CYCRIN 14/14)	4826831	MAY 02, 2006	U-102	NP	DEC 30, 1997
>ADD>	20325 001	FAMOTIDINE; PEPCID AC	4283408	AUG 11, 2000		NS	APR 28, 1998
>ADD>	19834 001	FELODIPINE; PLENDIL	4803081	FEB 07, 2006			
>ADD>			4264611	APR 28, 1998	U-3	NCE	JUL 25, 1996
>ADD>	19834 002	FELODIPINE; PLENDIL	4803081	FEB 07, 2006			
>ADD>			4264611	APR 28, 1998	U-3	NCE	JUL 25, 1996
>ADD>	19834 004	FELODIPINE; PLENDIL	4803081	FEB 07, 2006			
>ADD>			4264611	APR 28, 1998	U-3	NCE	JUL 25, 1996
	19452 001	FLUOCINOLONE ACETONIDE; DERMA-SMOOTHE/FS				I-122	FEB 16, 1998
	20121 001	FLUTICASONE PROPIONATE; FLONASE	4335121	MAR 15, 2002		NCE	DEC 14, 1995
						NDF	OCT 19, 1997
>ADD>	20261 001	FLUVASTATIN SODIUM; LESCOL	5354772	OCT 11, 2011	U-109	NCE	DEC 31, 1998
>ADD>	20261 002	FLUVASTATIN SODIUM; LESCOL	5354772	OCT 11, 2011	U-109	NCE	DEC 31, 1998
>ADD>	19915 002	FOSINOPRIL SODIUM; MONOPRIL	4384123	MAY 17, 2000		I-92	MAY 02, 1998
>ADD>	19915 003	FOSINOPRIL SODIUM; MONOPRIL	4384123	MAY 17, 2000		I-92	MAY 02, 1998
>ADD>	19915 004	FOSINOPRIL SODIUM; MONOPRIL	5006344	APR 09, 2008			
>ADD>			4384123	MAY 17, 2000		I-92	MAY 02, 1998
			4337201	JUN 29, 2001		NCE	MAY 16, 1996

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20460 001	GANCICLOVIR; CYTOVENE	4507305	OCT 19, 1999	U-64	NDF	DEC 22, 1997
			4355032	MAR 16, 2003	U-64		
	20305 001	GRANISETRON HYDROCHLORIDE; KYTRIL	4886808	DEC 12, 2006	U-105	NCE	DEC 29, 1998
						NDF	MAR 16, 1998
>ADD>	20387 001	HYDROCHLOROTHIAZIDE; HYZAAR	5153197	OCT 06, 2009	U-3	NC	APR 28, 1998
>ADD>			5138069	AUG 11, 2009		NCE	APR 14, 2000
>ADD>	19842 001	IBUPROFEN; CHILDREN'S MOTRIN	5374659	DEC 20, 2011		I-123	MAR 24, 1998
>ADD>	20135 001	IBUPROFEN; MOTRIN	5320855	JUN 14, 2011		I-123	MAR 24, 1998
			5215755	JUN 01, 2010		NDF	NOV 16, 1997
>ADD>	20135 002	IBUPROFEN; MOTRIN	5320855	JUN 14, 2011		I-123	MAR 24, 1998
			5215755	JUN 01, 2010		NDF	NOV 16, 1997
>ADD>	20418 001	IBUPROFEN; MOTRIN				I-123	MAR 24, 1998
	18956 007	IOHEXOL; OMNIPAQUE 70	4396597	JUL 14, 1998			
			4250113	DEC 26, 1999			
>ADD>	20220 001	IOPRAMIDE; ULTRAVIST				NCE	MAY 10, 2000
>ADD>	20220 002	IOPRAMIDE; ULTRAVIST				NCE	MAY 10, 2000
>ADD>	20220 003	IOPRAMIDE; ULTRAVIST				NCE	MAY 10, 2000
>ADD>	20220 004	IOPRAMIDE; ULTRAVIST				NCE	MAY 10, 2000
	20225 003	ISOSORBIDE MONONITRATE; IMDUR				NDF	AUG 12, 1996
						NCE	DEC 30, 1996
	19816 002	KETOPROFEN; ORUVAIL				NDF	SEP 24, 1996
	19816 003	KETOPROFEN; ORUVAIL				NDF	SEP 24, 1996
	20241 001	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 002	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 003	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 004	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 005	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 006	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
>ADD>	20406 001	LANSOPRAZOLE; PREVACID				NCE	MAY 10, 2000
>ADD>	20406 002	LANSOPRAZOLE; PREVACID				NCE	MAY 10, 2000
	20011 001	LEUPROLIDE ACETATE; LUPRON DEPOT	4005063	JAN 25, 1996		I-119	MAR 30, 1998
	19670 001	LORATADINE; CLARITIN-D	4282233	AUG 04, 2000		NCE	APR 12, 1998
>ADD>	20386 001	LOSARTAN POTASSIUM; COZAAR	5153197	OCT 06, 2009	U-3		
>ADD>			5138069	AUG 11, 2009		NCE	APR 14, 2000
>ADD>	20386 002	LOSARTAN POTASSIUM; COZAAR	5153197	OCT 06, 2009	U-3		
>ADD>			5138069	AUG 11, 2009		NCE	APR 14, 2000

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19643 002	LOVASTATIN; MEVACOR	4231938	NOV 04, 1999		I-117	FEB 08, 1998
	19643 003	LOVASTATIN; MEVACOR	4231938	NOV 04, 1999		I-117	FEB 08, 1998
	19643 004	LOVASTATIN; MEVACOR	4231938	NOV 04, 1999		I-117	FEB 08, 1998
>ADD>	19962 001	METOPROLOL SUCCINATE; TOPROL-XL	5081154	JAN 14, 2009			
>ADD>			5001161	MAR 19, 2008			
>ADD>			4957745	SEP 18, 2007	U-107	NE	JAN 10, 1995
>ADD>	19962 002	METOPROLOL SUCCINATE; TOPROL-XL	5081154	JAN 14, 2009			
>ADD>			5001161	MAR 19, 2008			
>ADD>			4957745	SEP 18, 2007	U-107	NE	JAN 10, 1995
>ADD>	19962 003	METOPROLOL SUCCINATE; TOPROL-XL	5081154	JAN 14, 2009			
>ADD>			5001161	MAR 19, 2008			
>ADD>			4957745	SEP 18, 2007	U-107	NE	JAN 10, 1995
>ADD>	18654 001	MIDAZOLAM HYDROCHLORIDE; VERSED	4280957	DEC 20, 1999		I-125	APR 26, 1997
>ADD>	18654 002	MIDAZOLAM HYDROCHLORIDE; VERSED	4280957	DEC 20, 1999		I-125	APR 26, 1997
	20312 001	MOEXIPRIL HYDROCHLORIDE; UNIVASC				NCE	APR 19, 2000
	20312 002	MOEXIPRIL HYDROCHLORIDE; UNIVASC				NCE	APR 19, 2000
	20459 001	NALMEFENE HYDROCHLORIDE; REVEX				NCE	APR 17, 2000
	20459 002	NALMEFENE HYDROCHLORIDE; REVEX				NCE	APR 17, 2000
	20198 001	NIFEDIPINE; ADALAT CC	5264446	NOV 23, 2010			
	20198 002	NIFEDIPINE; ADALAT CC	5264446	NOV 23, 2010			
	20198 003	NIFEDIPINE; ADALAT CC	5264446	NOV 23, 2010			
	20356 001	NISOLDIPINE; NISOCOR				NCE	FEB 02, 2000
	20356 002	NISOLDIPINE; NISOCOR				NCE	FEB 02, 2000
	20356 003	NISOLDIPINE; NISOCOR				NCE	FEB 02, 2000
	20356 004	NISOLDIPINE; NISOCOR				NCE	FEB 02, 2000
	20145 001	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
	20145 002	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
	20145 003	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
	20145 004	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
	20145 005	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
	20145 006	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
>ADD>	19810 001	OMEPRAZOLE; PRILOSEC	4853230	NOV 02, 2005	U-108		
>ADD>			4786505	NOV 22, 2005	U-108		
>DLT>			~~4786505~~	~~NOV 22, 2005~~	~~U-37~~		
>ADD>			4255431	MAR 10, 2000	U-108		
	20007 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4695578	JAN 04, 2005		D-20	FEB 02, 1996

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20103 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4695578	JAN 04, 2005		NCE	JAN 04, 1996
						D-27	APR 10, 1998
						I-9	APR 19, 1998
	20103 002	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4695578	JAN 04, 2005		NCE	JAN 04, 1996
						D-27	APR 10, 1998
						I-9	APR 19, 1998
	20403 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4753789	JUN 28, 2005	U-44	D-20	FEB 02, 1996
			4695578	JAN 04, 2005		NCE	JAN 04, 1996
						I-9	AUG 13, 1996
	19901 001	RAMIPRIL; ALTACE	5061722	OCT 29, 2008	U-3		
	19901 002	RAMIPRIL; ALTACE	5061722	OCT 29, 2008	U-3		
	19901 003	RAMIPRIL; ALTACE	5061722	OCT 29, 2008	U-3		
	19901 004	RAMIPRIL; ALTACE	5061722	OCT 29, 2008	U-3		
	18703 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150				I-120	MAR 29, 1998
	18703 002	RANITIDINE HYDROCHLORIDE; ZANTAC 300				I-120	MAR 29, 1998
	19675 001	RANITIDINE HYDROCHLORIDE; ZANTAC	4585790	APR 29, 2003		I-120	MAR 29, 1998
	20095 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5028432	JUL 02, 2008		I-120	MAR 29, 1998
	20095 002	RANITIDINE HYDROCHLORIDE; ZANTAC 300	5028432	JUL 02, 2008		I-120	MAR 29, 1998
	20251 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5102665	APR 07, 2009		I-120	MAR 29, 1998
	20251 002	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5102665	APR 07, 2009		I-120	MAR 29, 1998
	20236 001	SALMETEROL XINAFOATE; SEREVENT	5380922	JAN 10, 2012			
	20240 001	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2001	U-3	NCE	DEC 29, 1999
	20240 002	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2001	U-3	NCE	DEC 29, 1999
	20240 003	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2001	U-3	NCE	DEC 29, 1999
	20240 004	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2001	U-3	NCE	DEC 29, 1999
>ADD>	19829 001	TECHNETIUM TC-99M EXAMETAZIME KIT; CERETEC	4789736	DEC 06, 2005		I-124	APR 07, 1998

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19057 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	MAR 15, 2011			
		5294615	MAR 15, 2011			
		5212176	MAY 18, 2010			
19057 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	MAR 15, 2011			
		5294615	MAR 15, 2011			
		5212176	MAY 18, 2010			
19057 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	MAR 15, 2011			
		5294615	MAR 15, 2011			
		5212176	MAY 18, 2010			
19057 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	MAR 15, 2011			
		5294615	MAR 15, 2011			
		5212176	MAY 18, 2010			
20347 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	MAR 15, 2011			
20347 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	MAR 15, 2011			
20347 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	MAR 15, 2011			
20347 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	MAR 15, 2011			
20439 001	TIMOLOL; BETIMOL	5231095	JUL 27, 2010		NP	MAR 31, 1998
20439 002	TIMOLOL; BETIMOL	5231095	JUL 27, 2010		NP	MAR 31, 1998
					NCE	MAR 03, 2000
20281 001	TRAMADOL HYDROCHLORIDE; ULTRAM				NCE	MAR 03, 2000
20281 002	TRAMADOL HYDROCHLORIDE; ULTRAM					
20388 001	VINORELBINE TARTRATE; NAVELBINE	4307100	DEC 22, 1998		NCE	DEC 23, 1999

New 15th Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

15TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 7542

Charge your order. It's easy!

MasterCard VISA

☐ **Yes,** please send me the following indicated subscriptions:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $64.00 per year.

The total cost of my order is $_____. Prices include regular domestic postage and handling and are subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐ – ☐☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
(Company or personal name)

_____
(Additional address/attention line)

_____
(Street address)

_____
(City, State, ZIP Code)

(_____) _____
(Daytime phone including area code)

_____
(Purchase Order No.)

_____
(Credit card expiration date)

Thank you for your order!

_____
(Authorizing Signature) (10/94)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2233.
To charge your subscription call (202) 512-1800.